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Abstract 
 Illicit drug use in the United States has shown no signs of abating, and the morbidity 
from drug abuse has risen sharply over the last several years.  This is primarily due to a rise in 
the abuse of opioids, including prescription opioids, heroin, and most recently, fentanyl.  Finding 
potential predictors of heroin use could help to reduce fatalities from drug overdose. 
 There have been many studies to identify correlates of heroin use, and most follow the 
same methodological pattern.  A literature search leads to a pre-selection of a set of predictors, 
which are then analyzed using traditional statistics – frequentist summaries and logistic 
regression.  This approach limits the potential for finding unexpected combinations of predictors, 
predictors that correlate with small subject classes, and previously undiscovered predictors.  The 
regression component of the approach is limited by the inability to accept the null hypothesis and 
it makes no use of information gathered during the literature search. 
 We propose an improvement to this approach.  We believe that principal component 
analysis and regression tree classification provide methods to objectively identify potential 
heroin use correlates from the data itself.  The information gained by these methods, combined 
with a review of existing research, allows us to create prior distributions for regressors.  We can 
then use Bayesian Markov Chain-Monte Carlo (MCMC) methods to build predictive models that 
are more robust than those from traditional approaches. 
 We demonstrated this approach by modelling the probability of heroin use based upon 
self-reported factors from a multiyear national dataset.  The ease of implementing classification 
and MCMC modelling allowed us to examine multiple years of data, which in turn enabled us to 
see how predictors of heroin use have evolved over time.  We found that our methods reinforced 
some beliefs, such as that OxyContin is correlated to heroin use.  We also found that they refuted 
other beliefs, such as that early age of use of drugs is strongly related to potential heroin use.  We 
found that certain usage patterns, such as polyabuse, easy access to heroin, and low perceived 
risk of heroin use are correlated to heroin use. 
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Introduction 
Evolution of the Opioid Epidemic 
 Illicit drug use has long been a problem in the United States.  Heroin, which was initially 
created as a medicine in 1898, has a particularly long history of abuse.  New York’s Bellevue 
hospital had its first admission for heroin addiction in 1910.  Federal government regulation of 
heroin began with the Harrison Narcotic Act in 1914, and by 1924, the US Congress banned all 
domestic manufacture of heroin (Scott, 1998).   
A century later, opioid use, including heroin, has seen a marked increase, and with that 
increase has come a dramatic rise in overdose deaths.  As shown in Fig. 1 below, in 1999, there 
were a total of 8,050 opioid-related deaths in the United States.  By 2016, that figure had risen to 
42,249.  While opioid overdoses have risen throughout this period, the steepest rise has occurred 
since 2013. 
Since the 1960s, the demographics of opioid users have changed.  Over time, the 
proportion of female heroin users has risen from less than 20% to around half of opioid users.  
The ethnicity of users has changed as well.  In the 1960s, whites made up half of heroin users 
seeking treatment, but by the 2010s, whites accounted for over 90% of treatment seeking users 
(Cicero, Ellis, Surratt, & Kurtz, 2014).  Although whites make up the largest share of heroin 
users, this epidemic affects all races, and opioid related death rates have increased for all 
ethnicities.  Fig. 2 below shows that while non-Hispanic whites retain the highest death rates, 
non-Hispanic blacks have seen a recent sharp increase. 
Figure 1:  Opioid Overdose Deaths (Henry J. Kaiser Family Foundation, 2018) 
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 One potential driver of this increase has been a change in usage patterns.  Since the 
middle of the last century, the way opioid abusers initiate their habits has changed dramatically.  
In the 1960s, over 80% of users’ first opioid abuse was with heroin.  In the 2000s, over 70% of 
users initiated abuse with prescription opioids.  This trend reversed somewhat in the 2010s as the 
heroin became the first opioid of abuse for 35% of users (Cicero et al., 2014).   
 The rise in opioid deaths has progressed in three overlapping phases as shown in Fig. 3.  
The first wave began with increased prescribing of opioids such as oxycodone and hydrocodone 
in the 1990s.  This increase occurred as attitudes shifted to help patients avoid pain despite a lack 
of objective studies to quantify the risks of an increase in opioid prescriptions (Wilkerson, et al., 
2016).  As a result, deaths due to this activity have increased since 1999.  Abuse deterrent 
formulas of opioids helped to reduce their misuse (Wilkerson et al., 2016), but other abuse 
patterns arose.  The second wave began in 2010 as heroin usage increased and caused a steep 
increase in overdose fatalities.  The third wave began in 2013 and has seen a dramatic rise in 
deaths due to synthetic opioids such as fentanyl.  Fentanyl, which is approved for cases of 
extreme pain, is 50 to 100 times more potent than morphine.  Fentanyl presents an extremely 
challenging situation because it is often mixed with heroin or cocaine without the knowledge of 
the user.   
For this study, we will focus on heroin usage.  This is because the cohort of 
acknowledged heroin users is sufficiently large to study across multiple years.  Also, because 
fentanyl use is often unintended, users may acknowledge heroin use in a survey while denying 
fentanyl use.   
Figure 2:  Opioid Death Rates by Race (Henry J. Kaiser Family Foundation, 2018) 
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We believe opioid deaths are avoidable.  Our goal is to classify individuals and predict 
their likelihood to use opioids, particularly the most dangerous ones such as heroin.  There are 
many possible correlates to heroin usage, including demographic variables such as race and sex, 
as well as behavioral variables such as the abuse of other illicit drugs or alcohol.  Other factors, 
such as income and level of education could play a role as well.  There are existing studies that 
identify correlates to heroin usage.  Our study will make use of the findings of these studies and 
improve upon the methods and modelling techniques that they used. Ultimately, our goal is to 
identify predictors that could be used by medical practitioners to identify individuals who are at 
risk for heroin use.  Those practitioners could then develop intervention strategies to reduce 
heroin use in America. 
Data Concerning Drug Use 
 Data about drug use and addiction in America, like all health data, is subject to 
limitations due to privacy concerns.  There are several types of datasets that can be used in 
research.  We can track the distribution of controlled substances in the United States through 
ARCOS (Automation of Reports and Consolidated Orders System), which is published by the 
Drug Enforcement Agency.  This system the monitors the flow of controlled substances from 
their point of manufacture through commercial distribution channels to point of sale or 
distribution at the dispensing/retail level - hospitals, retail pharmacies, practitioners, mid-level 
practitioners, and teaching institutions (US Department of Justice Drug Enforcement Agency, 
n.d.). 
Figure 3:  Waves of the Opioid Epidemic (Centers for Disease Control and Prevention, National 
Center for Injury Prevention and Control, 2018) 
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 Another category of data to explore is medical claims information.  Some states have 
mandated collection of claims and their publication in public datasets for researchers.  The 
APCD (All-Payer Claims Database) Council has collected links to states that have taken this 
step, and researchers can gather volumes of data directly from the states.  Medical claims data 
can also be obtained by working with managed care providers or insurance companies.  While 
these datasets are only specific to one set of patients, they can contain more detailed information 
than is found in public data. 
 The US Federal government collects vast amounts of data on subjects related to 
healthcare and makes these datasets available to researchers.  Studies include annual reports of 
vital statistics, surveys of health among specific categories of citizens, epidemiologic research, 
and many other valuable sources.1  For those who seek to investigate drug use and addiction, 
there has never been more information available to researchers, and it has never been easier to 
obtain.  
The National Survey on Drug Use and Health2 
 The Substance Abuse and Mental Health Services Administration (SAMHSA) is an 
agency within the U.S. Department of Health and Human Services whose mission is to reduce 
the impact of substance abuse and mental illness on America's communities (Substance Abuse 
and Mental Health Administration, n.d.).  SAMHSA was established by Congress in 1992 to 
make substance use and mental disorder information, services, and research more available.  
Since then, SAMHSA has administered and collected data and disseminated it to the public 
through written reports, online query tools, and full datasets. 
One of SAMHSA’s publications is the National Survey on Drug Use and Health 
(NSDUH).  NSDUH is an annually published dataset that is the result of a massive survey 
regarding substance abuse and mental health in the United States.  The NSDUH data has tracked 
the prevalence and correlates of drug use in the United States since 1971.  The goals of the study 
are to: 
• Provide accurate data on the level and patterns of alcohol, tobacco and substance use and 
misuse 
• Track trends in the use of alcohol, tobacco, and various types of drugs 
• Assess the consequences of substance use and misuse 
• Identify those groups at high risk for substance use and misuse 
NSDUH is used by many government agencies, private organizations, individual researchers, 
and the public at large.  Because the survey contains so many variables, it is an excellent dataset 
for exploration, and we have chosen to focus our study on NSDUH. 
                                                 
1 The National Institutes of Health publishes a list of databases at https://www.nlm.nih.gov/hsrinfo/datasites.html  
2 The following discussion refers to information in the NSDUH Codebook. 
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 NSDUH provides information about the use of illicit drugs, alcohol, and tobacco among 
members of the U.S. civilian, noninstitutionalized population aged 12 or older. The survey also 
includes several modules of questions that focus on mental health issues. Surveys have been 
conducted periodically since 1971, with the most recent ones in 1979, 1982, 1985, 1988, and 
annually from 1990 through 2014. Currently, public use files are available for surveys from 1979 
onward.  Due to improvements in the methodology of the survey, data from 2002 onward should 
not be compared to years prior to 2002.  Also, some changes to the survey in 2015 and 2016 
regarding prescription opioid use limit some comparisons between those years and the surveys 
from 2002-2014.  We restricted our analysis to 2003-2014 to work within these limitations and to 
allow us to construct four datasets with three years of information in each. 
 NSDUH’s sampling methodology is designed to capture as many geographic and 
demographic sections of the United States as possible.  Each observation in the resulting dataset 
contains a weight which researchers can use to extrapolate the observation to a section of the 
population.  The sum of the weights of the observations is equal to the population of the United 
States as measured by the most recent census.  Necessarily, the survey is huge -- in 2014, 
NSDUH contained 55,271 observations gathered from 67,901 interviews conducted by 700 field 
investigators.  There are some limitations to NSDUH: 
• The data are comprised of self-reports of drug use, and their value depends on 
respondents' truthfulness and memory 
• The survey is cross-sectional rather than longitudinal. That is, individuals were 
interviewed only once and were not followed for additional interviews in subsequent 
years. 
• Because the target population of the survey is defined as the civilian, noninstitutionalized 
population of the United States, a small proportion (approximately 3 percent) of the 
population is excluded. 
Nevertheless, the size, consistency over time, and thoroughness of NSDUH make it an 
exceptional resource for large dataset exploration. 
 NSDUH contains questions pertaining to drug usage history, mental health history, and 
demographic factors.  The dataset also contains variables that have been imputed by SAMHSA 
to reduce missingness and to improve the accuracy of results.  For example, if a respondent skips 
a question regarding whether she has ever used heroin but subsequently answers a question 
regarding the last time she used heroin, an imputed heroin use flag will be positive.  SAMHSA 
recommends that researchers use imputed variables rather than direct responses.  There are 
thousands of variables in the dataset -- in 2014, there were 3,148 variables for each observation. 
To facilitate research across multiple years, SAMHSA has released a single dataset 
containing the NSDUH survey results from 2002-2014.  We used this file for our study.  There 
are 722,653 observations in the dataset, and each observation has 3,625 variables. Because the 
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survey changes slightly each year, the variables selected for this dataset are consistent across 
multiple, but not always all, years in the range.   
 The richness of the data in NSDUH allows researchers to explore a great number of 
topics.  For example, data from 2005-2014 show that there has been an increase in binge 
drinking and alcohol use disorder among subjects aged 50 and over (Han et al., 2017).  Another 
study correlated drug use to employment, finding that subjects who were unemployed following 
the 2008 recession were more likely to have been marijuana users prior to losing their jobs 
(Compton, Gfroerer, Conway, & Finger, 2014).  Interestingly, this study also showed that 
NSDUH, despite being a self-reported survey, matches other objective data such as the National 
Bureau of Labor Statistics.  In summary, NSDUH is ideally suited to help us employ data science 
methods on a large dataset to seek new information regarding heroin use. 
Literature Review 
 The purpose of our literature review was twofold.  First, we sought to learn what 
correlates to heroin use have been identified in other studies.  This information helped to guide 
the assumptions that we used in exploring the NSDUH dataset.  Second, we desired to see what 
methods other researchers have used and whether we could improve upon those.  Due to the 
seriousness of the opioid epidemic, there is no shortage of studies that investigate correlates 
between heroin abuse and other factors.  Because victims of the opioid epidemic use prescription 
opioids (POs), heroin, and synthetic opioids, we chose to review literature that was not limited to 
heroin alone.   
Earlier Findings Regarding Opioid Abuse 
 Wilkerson et al. provide a summary of existing research and point out that there is a set of 
demographic characteristics that is tightly linked to opioid abuse.  Opioid users are more likely to 
be Caucasian (non-Hispanic white), men aged 18-25, Medicaid eligible, have low household 
incomes, and initiate abuse with non-medical use of POs (Wilkerson et al., 2016).   
Several studies use NSDUH data.  These studies show that heroin users tend to be non-
Hispanic whites, have used cocaine or POs within the last year, live in larger cities, and have 
either no health insurance or rely on Medicaid (Jones, 2013).  Similarly, an evaluation of 
NSDUH data across several years shows that heroin initiation is strongly related to prior abuse of 
POs, and while there is no racial difference in the likelihood of heroin use among PO abusers, 
heroin users who were not PO abusers were more likely to be non-Hispanic whites (Cerd, An 
Santaella, Marshall, Kim, & Martins, 2015).  Some researchers have used NSDUH to explore 
very specific topics.  For example, one study shows that heroin users were more likely to have 
had prior use of inhalants (Wu & Howard, 2007). 
 Other datasets regarding opioid abuse include electronic medical records, prescription 
data, and smaller scale surveys.  These datasets tend to be proprietary and are obtained from 
health care providers such as HMOs or state government records of hospital admissions.  Despite 
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their different origin, these datasets confirm the findings from studies of NSDUH.  PO abuse is 
linked to early first non-medical use of POs (McCabe, West, Morales, Cranford, & Boyd, 2007).  
Subjects with mental health disorders or other substance use disorders had a higher incidence of 
opioid abuse (Edlund et al., 2010).   
Some studies have found patterns that can be exploited in the treatment or prevention of 
abuse.  For example, opioid abusers tend to be male, receive prescriptions for opioids with more 
days of supply, receive more medical and psychiatric treatments, and are prescribed more 
concordant drugs with their opioid medications (Cochran et al., 2014).  Stumbo attempts to 
generalize combinations of factors by defining five pathways to opioid abuse (Stumbo, et al., 
2017): 
• Inadequately controlled chronic pain leads to misuse 
• Individual vulnerability to opioid dependence even after brief opioid exposure 
• Individuals with prior substance use problems who are prescribed opioids 
• Relief from emotional distress which reinforces misuse or abuse; and 
• Abuse begins with recreational or non-medically supervised use of opioids 
One way that knowledge of these factors has been used to reduce opioid abuse has been to 
restrict access to opioids via changes in prescriptions.  Subjects who have been prescribed opioid 
medications with lower days’ supply, lower average doses, and limitations to Type III and IV 
opioids have a lower likelihood of opioid abuse disorder (Edlund et al., 2010).   
Methodologies of Earlier Studies 
 Except for Cerd et al. (2015), all the aforementioned studies used a similar methodology.  
Each started with an assumed set of likely predictors of opioid or heroin abuse.  These assumed 
predictors were sometimes chosen from reviews of other studies, and sometimes the predictors 
were specifically chosen to test a hypothesis.  For example, the question “Do lower prescription 
amounts reduce the likelihood of opioid abuse?” calls for a very specific analysis.  The predictors 
were tested using frequentist techniques – researchers looked for differences in levels of the 
predictor between categories of outcome variables.  The significance of these differences was 
then tested with null hypothesis significance tests (NHST).  With a set of predictors in hand, 
researchers then built traditional regression models to determine how the factors changed the 
odds of belonging to an outcome category.  For example, regression results have shown that the 
odds of having a non-fatal overdose are much higher (adjusted odds-ratio = 3.68) for a user who 
injects opioids than one who doesn’t. 
 There are two areas for improvement in this approach.  First, datasets such as NSDUH 
contain a great number of potential predictors, which also means that there is an enormous set of 
interactions among these factors, any of which could be a very strong predictor.  If we can 
consider more factors, we may uncover findings which are less obvious.  We can also improve 
the accuracy of estimating the effect of any predictor.  We already know that many studies have 
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shown that prior non-medical use of POs is associated with heroin use.  We should take such 
knowledge into account when conducting analyses that compare the odds of heroin or opioid 
abuse.   
 Classification and regression tree analysis (C&RT) provides one way of identifying 
factors and combinations of factors that can be predictors.  C&RT analysis is a way to explore 
the relationships between an outcome variable and many potential predictors.  The method starts 
by finding the most significant predictor variable that splits observations (branching) into two 
mutually exclusive subgroups (nodes).  Each element of a node has the same value for the 
outcome variable as every other member.  The method proceeds to then divide each one of the 
nodes into two other nodes and continues in this fashion until each lowest node (leaf) is 
completely homogenous, or as is more likely, some stopping criterion is satisfied. 
 Tree-based and rule-based methods generate models that are easy to interpret.  They can 
also handle many types of predictors, including nominal, ordinal, and interval variables, and 
those predictors don’t need to be pre-processed.  Tree-based models also do not require to user to 
assume the underlying distribution of the predictor (Kuhn & Johnson, 2013).  When examining 
datasets with many variables, and which have many potential interactions between those 
variables, C&RT is an effective way to reduce the number of interactions for further 
consideration (Piper, Loh, Smith, Japuntich, & Baker, 2011).  For these reasons, C&RT methods 
are an ideal way to for us to identify potential predictors from NSDUH, a dataset containing 
thousands of variables.  Indeed, other authors have advocated that classification trees should be 
used for data mining medical data (Koh & Tan, 2005).  However, C&RT has some drawbacks – 
it is subject to model instability as data change and has sub-optimal predictive performance.  
Therefore, it should be seen as complimentary to other methods, such as regression, rather than 
as a replacement for them (Fernández, Mediano, García, Rodríguez, & Marín, 2016; Piper et al., 
2011). 
 C&RT has occasionally been used in medical studies.  For example, one study of HMO 
data found that subjects of 24-25 years old with at least three prescriptions from at least three 
different pharmacies were more likely to have abuse-related diagnoses (Chitwood-Dagner, 
Carlson, Friedman, & Skatter, 1995).  C&RT’s flexibility can be seen in the range of medical 
studies in which it has been applied.  Some of these include predicting mastitis (Fernández et al., 
2016), tobacco smoking relapse (Piper et al., 2011), HIV risk analysis (Frisman, Prendergast, 
Lin, Rodis, & Greenwell, 2008), and the impact of religiosity in avoiding suicide in Iran 
(Baneshi et al., 2017). 
 There are assertions that Bayesian methods are superior to traditional methods such as 
NHST and regression for medical studies.  Bayesian methods are better for sparse data, and the 
use of prior distributions allows for the inclusion of regressors that might otherwise be excluded 
by p-value selection (Greenland, 2007).  Traditional methods also don’t have the ability to prove 
null hypotheses because p-values don’t change with the addition of additional results in favor of 
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the null.  In contrast, Bayesian techniques, such as the use of the Bayes Factor to compare 
models, allow the proof of nulls (Dienes, 2008). 
 Perhaps the best reason to use Bayesian techniques is the ability to use prior knowledge 
in the construction of predictive models.  In our case, we already know that abuse of POs is a 
strong predictor for heroin use.  If our model includes PO abuse as a predictive variable, we can 
use a prior distribution that is positive for the effect of PO abuse when we calculate odds ratios 
via Markov Chain-Monte Carlo (MCMC) analysis.  Taking advantage of prior knowledge 
requires a careful approach.  Priors should be fair, well reviewed, and should consider previous 
studies (Dienes, 2008; Greenland & Poole, 2013).  Even though they are difficult to construct, 
informed priors, even weak priors, are better than equal odds priors or frequentist methods, 
which assume no prior knowledge at all.  The assumption of no prior knowledge is inappropriate 
for most medical studies (Greenland & Poole, 2013).   
 While setting priors could be complex, we can adopt some simplifying methods to 
estimate a weakly informative distribution.  One suggestion for the construction of priors is to 
have three categories: “uncertain”, “probably positive”, and “probably strong”.  The prior for 
each category would be of the form 𝑃(𝑝𝑎𝑟𝑎𝑚𝑒𝑡𝑒𝑟)~𝑓(𝑀𝑒𝑑𝑖𝑎𝑛 = 𝑚, 𝑣𝑎𝑟𝑖𝑎𝑛𝑐𝑒 = 𝑣).  The 
variance for “uncertain” would be the highest, and the one for “probably strong” would be the 
lowest (Greenland, 2007).  Another even simpler method for setting priors would be to take an 
estimate of the mean of a predictor, round that value up to the next “large” value, and set a 
standard deviation equal to half of that value (Dienes, 2008). 
We propose a better way to conduct analyses of drug abuse data than the traditional ones we 
saw in the literature search.  We shall combine classification and regression tree (C&RT) 
methods with Bayesian MCMC methods.  C&RT will allow us to uncover likely heroin use 
correlates without overly limiting the vast set of variables in NSDUH to consider.  C&RT will 
also allow us to find combinations of variables that are potential correlates.  Some of these 
correlates will match those found in earlier studies.  For those, we will develop prior 
distributions that recognize their impact on heroin use.  We will then use MCMC methods to 
determine posterior distributions and odds ratios for the correlates that make use of those 
informed prior distributions.  This approach should be more comprehensive and accurate than 
traditional methods. 
Methods 
 The goal of our study is to construct a model that can define the probability of heroin use 
based upon the values of a set of variables from the NSDUH dataset.  We used this model on 
multiple datasets that span different blocks of years to see if the predictors of heroin use have 
evolved over time.  There are four steps in this process:  dataset preparation, variable selection, 
model construction, and model validation.  In dataset preparation, we reduced the NSDUH 2003-
2014 dataset, which consists of 722,653 observations and 3,625 variables, into four smaller 
datasets.  Each of these datasets contained three years of data and a useful and manageable 
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collection of variables.  In variable selection, we considered each three-year dataset and 
extracted a set of variables that is relatively small yet best correlates with heroin usage.  In model 
construction, we determined how changes in each of those variables are related to changes in the 
probability of heroin usage over a three-year period.  In model validation, we applied our model 
to dataset samples that we held out from model construction and evaluated the accuracy of its 
predictions. 
Dataset Preparation 
Sections of the NSDUH Dataset 
 Each observation in the NSDUH dataset represents information about a single 
respondent.  The variables in the dataset are data about the respondent.  The variables for each 
observation are organized into sections.  The first is the group of responses by the participant to 
questions related to substance use.  SAMHSA calls these “self-administered substance use” 
questions, and they cover topics such as age of first use, frequency of use, and other usage 
characteristics for each of a great number of substances.   
The second section consists of variables that are imputed by SAMHSA from the first set.  
SAMHSA recommends the use of the resulting imputed variables for multivariate analyses 
(SAMHSA, 2016).  We used imputed variables and ignored self-administered variables 
whenever possible. 
There are several other self-administered sections that provide information beyond simple 
substance use statistics.  These include treatment history, social environment factors, youth 
experiences, mental health and depression history, income, insurance coverage, and many other 
special topics.  As with the drug-use section, each special topic self-administered section is 
followed by a recoded section containing imputed variables. 
The demographic section of self-administered and imputed variables contains data about 
marital status, education level, and employment type, history, and environment.  Next, the 
dataset contains geographic variables regarding population density and whether the respondent is 
in an American Indian area.  The last section in the dataset consists of a set of weighting factors.  
These factors allow researchers to extrapolate information in NSDUH to the entire population of 
the United States.  For example, the first observation in the dataset has a one-year weighting 
factor of 10773.49 – the values for the variables of that observation represent those of 
approximately 10,773 Americans.   
Manual Reduction of the Dataset 
 The first step in dataset preparation was to manually review all 3,625 variables, section-
by-section, to eliminate unnecessary or redundant predictors.  Whenever possible we used 
imputed values rather than self-administered ones to improve the accuracy of the data.  We also 
eliminated obvious duplicates and variables that recategorized values from other variables.  For 
example, the variable “ALCAFU” has values that represent categories of age-of-first-use of 
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alcohol.  One such value is “15-17 Years Old”.  This value occurs in observations for which the 
value of imputed alcohol age of first use (“IRALCAGE”) is 15, 16, or 17.  In cases like these, we 
kept the ordinal variable rather than the categorical variable. 
 We then eliminated substance-use variables for uncommon drugs that were also grouped 
together under another single variable.  One grouped variable is “BENZOS”, a binary variable 
that is true if the respondent has used any of the following drugs:  klonopin, clonazepam, Xanax, 
alprazolam, Ativan, lorazepam, valium, diazepam, Librium, limbitrol, rohypnl, serax, or 
tranxene.  In this case we were able to use one variable that represented a true answer for any of 
thirteen other variables.3   
 We did not include any of the weighting factor variables.  Our model seeks to find 
relationships between heroin and other predictors.  It does not seek to provide aggregate statistics 
regarding substance use, so there is no need to include the extrapolation factors.  Finally, we 
eliminated any variables that were obviously completely correlated with heroin use.  For 
example, we did not include frequency-of-use of heroin or age-of-first-use of heroin variables 
because they hold no meaning for respondents who have never used heroin. 
 We removed nine additional variables that did not have enough data to be considered in 
our study.  The impact of the manual reduction of the dataset was to drop the number of 
variables for consideration from 3,625 to 371. 
Manual Imputation and Modification 
 Even though SAMHSA conducted imputation that reduced errors and missingness, we 
were still left with missing values in our dataset.  Knowing that random forest classification trees 
must not have missing data, we chose to eliminate missing values directly.  Using the MICE and 
VIM package in the R programming language, we identified all variables that retained missing 
values.  There were 127 of these variables, most of which fell into one of three categories.  The 
first category was the set of variables that was specific to youths (under 18).  An adult 
respondent would have missing values for any variable that was only asked of youths.  The 
second category was specific to adults.  In this case, a youth respondent would have missing 
values for any variable that was asked only of adults.  In these two categories, we replaced 
missing values with “false”, 0, or whatever value would appropriately convey a negative 
response.   
The third category consisted of sets of variables that required specific intervention.  One 
such set indicates a respondent’s history with physical or mental ailments.  For example, the 
variable “HEPATLIF” is true if a respondent indicated that he had ever had hepatitis.  When we 
                                                 
3 We did not create any other groupings of substances beyond those contained in the NSDUH. 
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encountered missing values in this category, we again replaced them with “false”, 0, or an 
appropriately negative value.4   
Another block contained nominal variables with specific values for skips or refusals to 
answer.  The variable “TOTDRINK”, which represents the number of days a respondent used 
alcohol in the past twelve months, has the following values as shown in Fig. 4: 
There were 285,413 respondents who did not indicate how many days they had consumed 
alcohol in the past year.  From other variables, we know that 282,124 respondents said that they 
had not used alcohol in the past year.  Since these two values are very close, we conclude that 
blanks can be assumed to be 0.  Consequently, we simplified the “TOTDRINK” variable by 
replacing the values “994”, “997”, and “998” with 0.  We treated all such nominal variables in 
this manner. 
 Questions regarding treatment history had three potential answers – 0 if the respondent 
felt the need for treatment but didn’t receive it, 1 if the respondent received treatment, and 
missing if the respondent didn’t answer or didn’t feel the need for treatment.  We replaced the 
missing value with -9, a value that is used throughout the NSDUH dataset to indicate questions 
that were not asked in a given year.  We also used this method with other variables that 
contained missing as a valid answer – we replaced missing with -9. 
 Questions regarding the ability to obtain substances had three possible values: 1 =  
“Fairly or Very Easy”, 0 = “Other”, or missing, which represented “Unknown”.  We replaced 
missing with 0 for these questions.  By doing this, we are allowing the most interesting response, 
“Fairly or Very Easy”, to maintain its impact.  We used this method with other blocks of 
similarly structured questions, such as the group regarding a respondent’s perception of the risk 
associated with use of specific substances. 
 The last category of variables we imputed manually included questions regarding needle 
use and crime.  These questions were worded in a way that should have generated a binary 
response.  The question regarding cocaine needle use was, “Have you ever, even once, used a 
needle to inject cocaine?”  The answers included:  “YES”, “NO”, “YES (Logically assigned)”, 
                                                 
4 Because the distribution of positive responses for these variables was so low, we assumed that 
that correct answer for a skip was most likely negative. 
Value Interpretation Frequency
Range from 1-372 Number of days used alcohol 433,507
994 Don't know 2,977
997 Refused 756
998 Blank (No answer) 285,413
TOTDRINK Variable
Figure 4:  Variable with Missing Values 
Beattie | 13  
 
“BAD DATA”, “NEVER USED COCAINE”, “DON’T KNOW”, “REFUSED”, and “BLANK 
(No answer)”.  We simplified this set of answers to simply “YES” and “NO”.  The number of 
“BAD DATA”, “DON’T KNOW”, “REFUSED”, and “BLANK” values represented less than 
0.02% of all answers, so assigning them to “NO” maintained the integrity of the data.  Questions 
regarding whether a respondent had committed a particular crime were similarly structured.  We 
manually imputed the values for these variables into binary values as well. 
 The combination of these interventions and imputations left us with a dataset containing 
no missing values and a cleaner set of answers to straightforward questions.  The final manual 
change we made was to eliminate observations from 2002.  We did this to prepare the dataset for 
separation into three-year blocks:  2003-2005, 2006-2008, 2009-2011, and 2012-2014. 
Data Preparation:  Exploration 
 Before conducting variable selection with classification tree methods, we wanted to see if 
there were any patterns that we could identify in the data that would influence our analysis.  
Specifically, we wanted to determine the following: 
• Are there any variables that explain so much of the variance of the data that they warrant 
special handling? 
• Which variables are so highly correlated to each other that they can be combined? 
In this step, we needed an efficient method that could provide us answers to these two questions 
in an unsupervised fashion.  We elected to use Principal Component Analysis, a method that 
satisfies these criteria. 
Principal Component Analysis Review 
 Principal Component Analysis (PCA) is a method that is used to simplify high-dimension 
multivariate data analysis.  PCA transforms possibly correlated variables into a smaller number 
of uncorrelated features called principal components.  The first principal component accounts for 
as much variation in the original dataset as possible, and each subsequent component accounts 
for the next most amount of variation.   
PCA is an efficient technique because it is ultimately a solution to a set of linear 
equations.  If we let 𝑿 be an 𝑚 𝑥 𝑛 matrix of our data, where m is the number of observations 
and n is the number of variables, then the covariance matrix for our data is given by: 
𝐒 = cov(𝐗) = E[(𝐗 − E[𝐗])(𝑿 − 𝐸[𝑿])𝑇 
and 
𝑾−1 𝑺𝑾 = 𝑫 
where 𝑾 is the set of eigenvectors of 𝑺, and 𝑫 is a diagonal matrix of the eigenvalues of 𝑺.  The 
ith eigenvector 𝑤𝑖 is the ith principal component of our original dataset.  The ith eigenvalue λ𝑖, 
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where ∑ λ𝑖𝑖 = 1, describes the proportion of variance of the original data that is explained by 𝑤𝑖.  
For example, if λ𝑖 = 0.20, then the principal component given by 𝑤𝑖 explains 20% of the 
variance of the data. 
 There are some drawbacks to using PCA to explain data.  First, the method will favor 
components that have more variation.  In our case, this means that variables with a wider range 
of values will tend to fall on the first components.  We can compensate for this effect by z-score 
standardizing the variables in the dataset so that each variable will have a mean of zero and 
standard deviation of 1: 




Another drawback is that the features generated by PCA are complex linear combinations of all 
the variables in the dataset.  In our case, each feature would be a function of 371 variables.  
These features are hard to interpret and do not allow us to make explanatory conclusions 
regarding heroin use.  That said, the features do satisfy the goals of our exploration. 
Principal Component Analysis Results 
Results from the First Pass 
 We conducted three passes of PCA on the NSDUH dataset.  In each case, we randomly 
selected 25% of the observations from the 2003-2014 dataset for consideration.  We then used 
the PCA() function from the R package FactoMineR (Husson, Josse, Le, Mazet, & Husson, 
2018) to determine the principal components and their corresponding eigenvalues.  We 
conducted a preliminary run that showed the effect of the components decreases significantly 
after the first three.  To ensure we captured the most important components for each run, we set 
the ncp (number of principal components) parameter for PCA() to ten.  We analyzed the results 
for each pass to determine the twenty most positively and twenty most negatively correlated 
variables for each component.  From this information we determined whether to remove any 
variables from the dataset or to restructure it entirely.  In this section we will describe in detail 
our analysis of the first pass to illustrate our methodology.  We will then summarize our findings 
for the second and third passes. 
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 In the first pass, we started with the manually reduced 2003-2014 dataset:  668,574 
observations with 371 variables.  We then z-scored the dataset and extracted a random sample of 
167,143 observations (25% of the total).  We ran PCA() on this dataset and found that 18 
principal components explained at least 50% of the variance in the dataset.  The first component 
explained 11.8% of the variance, the second accounted for 9.2%, and the third 5.9% (see Fig. 5). 
 
 The variables most positively correlated with the first component in the first pass were all 
related to respondents’ histories of physical illness.  The top twenty all had virtually identical 
correlation scores of 0.997.  The most highly correlated variable was whether the respondent had 
lung cancer in the past year (luncayr).  A raw value of 1 for luncayr indicated that she had, 0 
indicated that she hadn’t, and -9 indicated that data wasn’t collected for the year of that survey.  
Thus, respondents who had lung cancer were positively correlated with the first component.  
Similarly, the remainder of the top twenty positively correlated variables were responses to 
questions about illnesses such as cirrhosis, tuberculosis, pancreatitis, and HIV. 
 The variable most negatively correlated with the first component indicated whether the 
respondent had ever used oxycontin (OXYCONT25).  This variable was highly negatively 
correlated and had a score of -0.997.  Because the next most negative variable had a score of -
0.069, we conclude that oxycontin use dominated the negative correlation of the component.  A 
raw value of 1 for OXYCONT2 indicated that the respondent had used oxycontin, 0 indicated 
that he hadn’t, and -9 indicated that the data wasn’t collected in that year. 
 Interpreting the principal components in this analysis is challenging due to the number of 
variables involved, but we surmise that each represents a set of features of respondents that 
collectively can describe a sub-population.  In the case of the first component of the first pass, 
we see that respondents who have had physical illness but have not ever used oxycontin account 
for the most variability in the dataset. 
 The variables that most positively correlated with the second component included 
ismother and isfather, which had values of 1 if the mother or father was in the household, 2 if 
                                                 
5 We will see later that this variable was problematic. 
First Pass
Total Youth Adult Youth Adult
Components to Explain 
50% Variance
18 30 29 33 37
First Component 
Variance
11.8% 10.2% 8.9% 10.2% 8.8%
Second Component 
Variance
9.2% 4.6% 4.5% 3.7% 3.5%
Third Component 
Variance
5.9% 3.7% 4.2% 3.6% 3.1%
Second Pass Third Pass
NSDUH PCA Analysis
Figure 5: Variance Explained by Principal Components 
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not, 3 for ‘don’t know’, and 4 if the respondent was 18 or older.  ismother and isfather were most 
correlated with the component when a parent was not in the house.  The next set of positively 
correlated variables were flags that indicated the use of marijuana, cigarettes, hallucinogens, and 
alcohol. 
 The variable that was most negatively correlated with the second component included a 
youth’s participation in youth activities, where a high value indicated participation.  The next 
two were a flag indicating that the respondent was between 12 and 17 years of age and another 
flag indicating that the respondent was a youth.  The third most negatively correlated flag was 
one that indicated whether a youth had seen a drug prevention message outside school. 
 The third principal component was like the second.  It was dominated by variables that 
were specific to youths.  Its primary difference from the second component was that it was 
reversed in direction. 
Interpreting the First Pass 
 The first pass of PCA provided us with information that enables us to improve the 
preparation of the data for classification and regression trees.  The first component was 
dominated by physical illness flags, all of which were almost identically correlated with the 
component.  When we examined the number of positive respondents for any of these flags, we 
saw that the numbers were very low.  For example, the number of respondents who had lung 
cancer in the past year was only 207, and only 9 of those had ever used heroin.  We concluded 
that we could simplify the dataset by replacing all the individual physical illness flags with one 
flag, PHYSICKEVR.  This flag would equal 1 if the respondent had indicated that she had at 
least one of the individual physical illnesses, and 0 otherwise.  We also replaced the individual 
mental health flags with one summary flag, MHSICKEVR.  This flag would equal 1 if the 
respondent had ever had anxiety or depression, and 0 otherwise. 
 The second and third components were both dominated by variables specific to youth.  
Here the PCA presented us with information that we should have caught in the manual reduction 
of the dataset.  The NSDUH survey contains large sections that are age-specific.  There are 
blocks of questions that are reserved for youths (respondents under the age of 18) that are not 
asked of adults.  There are also blocks of questions reserved only for adults.  To retain these 
variables, we must therefore split the dataset into two portions – one containing youth 
respondents and one containing adult respondents. 
 After the first pass of PCA, we were able to eliminate a large group of variables through 
consolidation and we split the dataset into two subsets.  We then had one dataset for youths that 
contained 212,558 observations with 331 variables, and one dataset for adults with 456,016 
observations with 351 variables. 
Results from the Youth Second Pass 
 We ran both the youth and adult datasets through the second pass of PCA and again 
found variables we could remove from the dataset.  The first thirty components explained 50% of 
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the variance in the youth dataset.  The first component accounted for 10.2% of the variance, the 
second 4.6%, and the third 3.7%.  The variables most positively correlated with the first 
component were led by the flag indicating hallucinogen use, whether the respondent needed 
treatment for drug or alcohol use during the past year, whether the respondent had ever used 
psychotherapeutics (a category including sedatives, tranquilizers, stimulants, and analgesics), 
and two variables that both indicated the number of days the respondent had used marijuana in 
the past year.  The variables most negatively correlated with the first component were all drug 
and alcohol specific age-of-first use indicators.  The first component therefore represented drug 
and frequent marijuana users who began their substance use at an early age. 
 The most positive correlates to the second component were variables that indicated why a 
respondent did not receive treatment for drug and alcohol use despite feeling the need.  The 
negative correlates were led by flags indicating the respondent did not feel the need for treatment 
for drug and alcohol use.  These were followed by flags indicating alcohol and tobacco use in the 
past year.  The second component represented users who felt the need for substance abuse 
treatment, didn’t receive that treatment, and had low levels of alcohol use. 
 The third component represented respondents who had suffered mental illness or physical 
illness, indicated sources of sedatives, stimulants, or tranquilizers, had used oxycontin, had no 
cigarette use, and had not received treatment for mental health illness in the prior year. 
Results from the Adult Second Pass 
 The first 29 components explained 50% of the variance in the adult dataset.  The first 
component accounted for 8.9%, the second 4.5%, and the third 4.2%.  The positive correlates to 
the first component were flags indicating the use of specific drugs, the most positive of which 
was the flag for psychotherapeutics.  The negative correlates were the specific drug age-of-first-
use variables.  The first component represented drug users who began their use at an early age. 
 The second component of the adult dataset represented users who felt the need for mental 
health treatment, did not receive that treatment, and supplied reasons for not doing so.  These 
respondents also did not smoke or use hallucinogens.  The third component represented 
respondents who felt the need for drug and or alcohol abuse treatment yet didn’t receive it for 
various reasons.  These respondents also described reasons for not receiving treatment for mental 
health illness. 
Interpreting the Second Pass 
 Both the youth and adult datasets had similar principal components in the second pass.  
They both contained components that had nearly identically correlated variables indicating 
reasons for not receiving mental health or substance abuse treatment.  The number of positive 
responses for any one of these variables was very low.  For example, the total number of adults 
across all years who did not receive substance treatment because they didn’t feel the need for it 
(despite abuse) was only 287, and only 26 of those had ever used heroin.  We concluded that we 
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could drop the variables for specific reasons for not receiving mental health or substance 
treatment without impacting our analysis of heroin use. 
 We also uncovered some anomalies with specific variables.  We discovered that the flag 
for psychotherapeutics was redundant.  It duplicated responses to the individual drug use 
questions for sedatives, tranquilizers, stimulants, and analgesics.  We decided to simplify the 
dataset by removing he psychotherapeutic flag.  Also, we discovered that there were two 
different imputed variables for oxycontin use:  oxyflag and OXYCONT2.  The second of these, 
OXYCONT2, involved additional data manipulation by SAMHSA in the preparation of 
NSDUH.  Because the imputation methodology for oxyflag was the same as that for other drugs, 
we dropped OXYCONT2 in favor of oxyflag.  Also, we found a set of substance frequency use 
variables that were duplicated by imputed frequency variables.  We eliminated the non-imputed 
variables from the dataset.  With these changes, the adult dataset was reduced to 301 variables 
and the youth dataset was reduced to 296. 
Results from the Youth Third Pass 
 The third and final PCA pass on the youth dataset produced 34 components that 
explained 50% of the variance of the dataset.  The first component accounted for 10.1% of the 
variance, the second accounted for 3.8%, and the third 3.6%.  The variables most positively 
correlated with the first component included whether the respondent had used hallucinogens, 
whether he had needed substance abuse treatment in the past year, the frequency of his marijuana 
use in the past year, whether he had hallucinogen and marijuana use in the past year, and whether 
he had ever used hydrocodone products.  The most negatively correlated variables were age-of-
first use variables and the level of alcohol use in the past month (higher values indicated lower 
use).  The first component represented youths who were recent users of hallucinogens and/or 
marijuana, began drug use early, were binge drinkers, and needed substance abuse treatment in 
the past year. 
 The variables most positively correlated to the second component included whether a 
respondent had ever been mentally ill, physically sick, indicated sources for nonmedical use of 
drugs, and had used oxycontin in the past year.  The most negatively correlated variables were 
whether the respondent had ever used cigarettes, had received in-patient mental health services in 
the past year, had recent alcohol and/or cigarette use, and had a perceived great risk of LSD use.  
The second component represents youths who had been ill but not received treatment, were 
substance abusers, used oxycontin, and had a low perceived risk of drug use.  The third 
component represented tobacco users who began their use early but did not have recent use of 
smokeless tobacco or snuff. 
Results from the Adult Third Pass 
 The third PCA pass on the adult dataset produced 36 components that explained 50% of 
the variance.  The first component accounted for 8.8%, the second 3.6%, and the third 3.1%.  
The variables most positively correlated to the first component were variables that indicated that 
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the respondent had ever used hallucinogens, cocaine, pain relievers, tranquilizers, and 
hydrocodone products.  The most negatively correlated variables were age-of-first use variables 
for various substances.  The first component represents respondents who were drug users and 
who had started their use early. 
 The variables most positively correlated to the second component included whether the 
respondent had ever been mentally or physically ill, indications of sources of stimulants and 
tranquilizers, and indications of recent oxycontin use.  The negatively correlated variables 
included whether the respondent perceived great risk of frequent marijuana use, participated in 
government assistance programs (low values indicate participation), had easy access to LSD, and 
had been prescribed medicine for mental health illness in the past year (low values indicate 
prescriptions).  The second component represents respondents who had been sick, used 
oxycontin, had received prescriptions for mental health illness, were on government assistance, 
and did not perceive risk from frequent marijuana use.  The third component represents 
respondents who began tobacco use early, do not drink heavily, and had no recent smokeless 
tobacco or snuff use. 
Interpreting the Third Pass 
 The completion of the third pass of PCA demonstrated that we now had two datasets 
without unnecessary and highly correlated variables.  We did not identify any further needs for 
variable elimination, and we had well defined components.  Consequently, the adult and youth 
datasets were ready for the next stage of our study, classification and regression tree analysis.  
The youth dataset now consisted of 212,558 observations and 296 variables.  The adult dataset 
contained 416,016 observations and 301 variables.  Fig. 6 summarizes the top three components 
in the final datasets. 
 
Observations Variables First Second Third
Youth 212,558 296
Recent drug users 
who began use early, 
were binge drinkers, 




illness, had used 
oxycontin, and had a 
low perceived risk of 
drug use
Tobacco users who 
began use early but 
who had not had 
recent use of 
smokeless tobacco or 
snuff.
Adult 416,016 301
Drug users who began 
their use early
Oxycontin users who 
had been sick, 
received prescriptions 
for mental illness, did 
not perceive risk from 
frequent marijuana 
use, and who were on 
government 
assistance.
Tobacco users who 
began use early, did 
not drink heavily, and 
who had not had 
recent use of 
smokeless tobacco or 
snuff.
Dataset
Principal Component DescriptionDataset Size
Figure 6: Dataset Split and Principal Components 
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Separation into Three-Year Blocks 
 To evaluate changes in heroin usage over time, we separated the post-PCA 2003-2014 
datasets into several smaller datasets.  Heroin usage is relatively rare, and we wanted to have as 
many users as possible in each dataset while still allowing us to analyze changes over time.  
Based upon a recommendation from SAMHSA, we split the file into three-year blocks:  2003-
2005, 2006-2008, 2009-2011, and 2012-2014. 
 
Variable Selection by Random Forests of Conditional Inference Trees 
Review of Tree-Based Methods 
 The next step in our study was to select a set of variables that we could carry forward into 
a Bayesian regression model.  In the previous step, data exploration through PCA, we found 
variables that explained much of the variance in the total datasets.  In this step, we sought to 
identify variables that most explain the difference between heroin users and non-users.  
Throughout the rest of this study, we refer to these variables as important. 
 Tree-based models are well suited for this task for several reasons.  They are easy to 
implement and generate results that are easy to interpret.  They can handle many types of 
predictors without the need to pre-process them.  This is important in our case because our 
datasets contain binary, sequential, and categorical variables.  Tree-based models also do not 
require the investigator to specify the relationship between the predictor and response variables 
(Kuhn & Johnson, 2013). 
 The oldest and most common tree method is the Classification and Regression Tree 
(CART) method (Breiman, et al. 1984).  In this method, the model starts with the entire dataset, 
S, and searches every value of every predictor to find the combination of predictor and value that 
















Figure 7: Data Subsets by Time Period 
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SSE = ∑(𝑦𝑖 − 𝑦1̅̅ ̅)
2
𝑖ϵ𝑆1




𝑦1̅̅ ̅ and 𝑦2̅̅ ̅ are the average outcomes of the response variables within the two sets 𝑆1 and 𝑆2.  The 
method then partitions the subsets and continues recursively partitioning until a stopping 
criterion, such as minimum number of set members, is reached. 
 CART has some limitations.  One that affects our study is that the method tends to favor 
predictors with large numbers of distinct values.  This is because the method maximizes a 
splitting criterion across all possible splits simultaneously (Hothorn, Hornik, & Zeileis, 2006).  
In our case, we have predictors, particularly the age-of-first-use variables, that have many 
different values.  These predictors could be inappropriately assigned high importance by CART.  
To avoid this, we used conditional inference trees, which eliminate the bias towards many-values 
correlates by splitting variable selection and variable splitting into two separate steps (Hothorn et 
al., 2006).  A simplified version of the conditional inference tree algorithm is: 
1. Test the global null hypothesis that the variables 𝑋𝑗ϵ𝑿 in the dataset S are independent 
from the values of the response variable Y.  Use hypothesis testing and a threshold 
parameter, such as a p-value, to test for independence.  If the global null hypothesis 
cannot be rejected, stop.  Otherwise select the predictor 𝑋𝑗 with the strongest association 
to the response variable. 
2. Find the optimal binary split of the values for 𝑋𝑗 into 𝑋𝑗1 and 𝑋𝑗2 so that S can be 
partitioned into two subsets such that all values of 𝑋𝑗 in 𝑆1ϵ𝑋𝑗1, and all values of 𝑋𝑗 in 
𝑆2ϵ𝑋𝑗2.  The values for the response variable Y are homogenous within each of the two 
subsets 𝑆1 and 𝑆2. 
3. Recursively repeat steps 1 and 2. 
Another limitation of tree-based models is that single-tree models are unstable.  If the 
data on which they are designed alters slightly, the model can produce very different splits 
(Breiman, 1996b).  In our case, this means that single-tree models can be highly dependent on 
the selection of training data from the dataset.  Breiman (1996a) proposed bagging, a way to 
reduce the variance of predictions of individual trees.  He did this by building trees from 
bootstrap samples of the modeling dataset and then averaging the prediction across the trees.  
This method still has a drawback – because at each step the algorithm considers all possible 
predictors, the individual trees built from the bootstrap data can still be structurally similar.  We 
can overcome this drawback by randomly selecting a set of possible predictors at each step of 
tree construction.  Breiman (2001) developed an algorithm that unified bootstrapping and 
random predictor selection – random forests.  The remaining drawback of the random forest 
algorithm is that the ensemble of trees it uses for prediction is no longer easily interpretable as a 
simple set of binary splits.  However, the method provides stable variable importance scores that 
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we can use to select the most important variables from the model for our Bayesian regression 
analysis. 
Results from Random Forest Modelling:  Adults 
We used the random forest algorithm with the conditional inference tree method of 
selecting predictors and split values.  To run this algorithm, we used the cforest() method from 
the ‘party’ package (Hothorn, 2018).  This method allows the user to select the number of trees 
used to build the forest (‘ntree’), the number of predictors to sample at each step (‘mtry’), and 
runs in R.  We ran cforest() in a powerful compute environment – a Microsoft Data Science 
Azure virtual machine with 8 CPUs and 16 GB of RAM.  This VM includes R libraries that are 
designed to run multiple threads and take advantage of multiple processors.   
In this compute environment, the cforest() routine ran quickly, but the Predict() method 
in the ‘party’ package consumed a great deal of memory and wouldn’t complete when more than 
20,000 observations were involved.6  We were able to build models using a variety of sizes for 
our training set, but the evaluation of those models was limited to a random sample of 20,000 
observations for both the training and test sets of data. 
We ran several iterations of random forest on the 2003 to 2005 adult dataset to determine 
the best tuning parameters for the algorithm.  To evaluate the models, we examined three 
statistics:  the training set κtrain, the test set κtest, and the Area Under the Receiving Operator 
Characteristic curve (AUROC).  κ describes the relationship between the observed accuracy of 
the model and the expected accuracy, which is the accuracy of a random classifier given the 





The maximum value for κ is 1, and higher values of κ indicate better performance of the model. 
 AUROC is a function based upon the specificity and sensitivity of the model, which are 









                                                 
6 In contrast, we found that the CART based random forest routines, rforest() and predict(), were able to run 
completely.  We nevertheless chose to work with cforest() to leverage the advantages of conditional inference tree 
methods. 
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Sensitivity is also known as the “True Positive Rate”.  (1 – specificity) is known as the “False 
Positive Rate”.  When we plot the True Positive Rate versus the False Positive Rate, we generate 
the Receiver Operating Characteristic (ROC) curve.  The area under this curve (AUROC) 
approaches 1 as the performance of a model improves.  As an example, the ROC curve for the 
second run we conducted on the adult 2003-2005 dataset is shown in Fig. 8.  The area under this 
curve is 0.9657. 
In summary, the steps we use to evaluate the random forest model are:    
1) Work with the 2003-2014 adult and youth datasets for parameter optimization 
2) Select a size for the training set, such as 20% or 35% 
3) Run the cforest() method on the training set to build a model 
4) Calculate the variable importance scores for the model 
5) Apply the model to a randomly chosen 20,000 observations from the training set 
and evaluate its performance by computing a confusion matrix 
6) Apply the model to a randomly chosen 20,000 observations from the test set and 
evaluate its performance by computing a confusion matrix 
7) Calculate κ𝑡𝑟𝑎𝑖𝑛 and κ𝑡𝑒𝑠𝑡 
8) Calculate AUROC for the test set 
9) Select the model with the best κ𝑡𝑒𝑠𝑡 and AUROC combination 
The results of the parameter optimization runs are shown in Fig. 9 below. 
Figure 8: Example ROC Curve 
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Figure 9:  Tuning Parameter Analysis 
The tuning parameters for the adult model that resulted in the highest combination of κ and 
AUROC were:  training set equal to 35%, mtry = 10, and ntrees = 300.   
Using Set Intersection to Validate Variable Choice 
 Each of the random forest trials provides a list of variable importance scores.  The lists 
vary somewhat from trial to trial.  Ideally, our final list of important variables would be common 
across the top variables from each of the trials of our model.  We can see if this is the case by 
comparing the top variables from the best performing trial (the one with the best κ and AUROC 
combination) to those from the other trials. 
We took the top 10% of variables from each of the adult dataset runs.  We then computed 





where 𝑆𝑖 is the set of top 10% of the variables from run i.  The distances from run to run and 



















1 Adult 2003-2005 111,561 25% 5 200 1.87 0.2 0.5766 N/A N/A N/A
2 Adult 2003-2005 111,561 25% 5 300 2.78 0.2 0.5821 0.4430 0.9657 0.4278
3 Adult 2003-2005 111,561 25% 10 200 2.19 0.2 0.6257 0.4673 0.9690 0.4528
4 Adult 2003-2005 111,561 25% 10 300 3.34 0.2 0.6203 0.4723 0.9687 0.4575
5 Adult 2003-2005 111,561 35% 5 200 3.52 0.2 N/A N/A N/A N/A
6 Adult 2003-2005 111,561 35% 5 300 5.23 0.2 0.5658 0.4408 0.9691 0.4272
7 Adult 2003-2005 111,561 35% 10 200 4.09 0.2 0.6063 N/A N/A N/A
8 Adult 2003-2005 111,561 35% 10 300 6.04 0.2 0.6063 0.4884 0.9707 0.4741
Tuning Parameters
Trial Comparison Jaccard
2 vs 1 0.8182
3 vs 2 0.7143
4 vs 3 0.7647
5 vs 4 0.7143
6 vs 5 0.7647
7 vs 6 0.7647
8 vs 7 0.8750
Intersection of 
All vs Union of All
0.4390
Figure 10: Trial 
Comparisons 
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For each iteration of random forest, between 70% and 80% of the top variables were common 
with the prior run.  44% of the top variables from the combination of all runs were common to all 
the runs.  This intersection of all the top variables was a set of 18 predictors.  To sort this list, we 
used the variable importance scores from the best performing random forest model, Trail 8.  The 
scores are shown in Fig 11. 
 
Of these 18 variables, all but MESC2 matched the top 18 variables in Trial 8, the run 
with the best κ and AUROC combination.  Due to this high level of agreement, we can conclude 
that selecting the top variables from the best performing model does indeed provide us with a 
valid way to select the variables for regression modelling.  We didn’t need to run multiple 
random forest models for remaining datasets – we just needed to run one model per dataset with 
the parameters:  training set equal to 35%, mtry = 10, and ntrees = 300.  Using these parameters, 
we identified the top twenty variables7, ranked by importance, for each of the multiyear datasets.  
The Adult Important Variables are shown in Fig. 12. 
                                                 





crkflag 3.99E-04 Crack - ever used
rdifher 3.99E-04 Heroin fairly or very easy to obtain
ircrkage 3.66E-04 Crack age of first use
cocneedl 2.47E-04 Ever used needle to inject cocaine
cocflag 1.89E-04 Cocaine - ever used
ircocage 1.61E-04 Cocaine age of first use
pcpflag 1.41E-04 PCP - ever used
irpcpage 1.25E-04 PCP age of first use
otdgnedl 9.41E-05 Ever used needle to inject any other drug
halflag 8.03E-05 Hallucinogens - ever used
txilalev 7.83E-05 Received treatment for drug or alcohol use in lifetime
lsdflag 7.60E-05 LSD - ever used
METHDON2 7.30E-05 Methadone - ever used
MORPHIN2 7.11E-05 Morphine - ever used
benzos 7.02E-05 Benzodiazepine products - ever used
irlsdage 6.17E-05 LSD age of first use
irtrnage 5.56E-05 Tranquilizer age of first use
MESC2 5.25E-05 Mescaline - ever used
Figure 11: Common Important Variables 
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The model fit results for the multiple datasets is given in Fig. 13. 
Results from Random Forest Modelling:  Youths 
 Selecting variables from the youth datasets was more difficult than from the adult 
datasets.  This is because the number of heroin users among youth NSDUH survey respondents 
was very low.  In 2003-2005, there were only 186 youth heroin users (out of 55,176 respondents) 
compared to 2,008 adult heroin users (out of 111,561 respondents).  Due to the low number of 
youth users, we could not get meaningful results when we split the data between training and test 
sets, even when we increased the training set size to 50%.  As seen in Fig. 14, the combination of 
κ and AUROC never went above 0.13, and the κ for the training set never surpassed 0.242.  We 
had to forego splitting the youth dataset into training and test components to have enough users 
to build a meaningful model.  When we did so, we obtained better values of between 0.4454 and 
0.6301 for the model.  As with the adult runs of PCA(), the youth runs would not complete 
prediction on test sets larger than 20,000 observations.   
Variable Importance Variable Importance Variable Importance Variable Importance
crkflag 3.99E-04 ircrkage 4.23E-04 ircrkage 3.75E-04 ircrkage 4.46E-04
rdifher 3.99E-04 cocneedl 3.46E-04 crkflag 3.54E-04 crkflag 4.32E-04
ircrkage 3.66E-04 crkflag 3.23E-04 cocneedl 2.35E-04 cocflag 2.92E-04
cocneedl 2.47E-04 rdifher 1.74E-04 cocflag 2.00E-04 cocneedl 2.87E-04
cocflag 1.89E-04 ircocage 1.67E-04 METHDON2 1.97E-04 otdgnedl 2.74E-04
ircocage 1.61E-04 cocflag 1.54E-04 ircocage 1.89E-04 rdifher 2.65E-04
pcpflag 1.41E-04 MORPHIN2 1.40E-04 otdgnedl 1.85E-04 ircocage 2.61E-04
irpcpage 1.25E-04 METHDON2 1.40E-04 MORPHIN2 1.41E-04 METHDON2 1.81E-04
otdgnedl 9.41E-05 pcpflag 1.22E-04 irlsdage 1.36E-04 OXYCODP2 1.59E-04
halflag 8.03E-05 lsdflag 1.17E-04 oxyflag 1.35E-04 iroxyage 1.49E-04
txilalev 7.83E-05 irpcpage 1.16E-04 lsdflag 1.31E-04 othanl 1.40E-04
lsdflag 7.60E-05 txilalev 1.04E-04 rdifher 1.24E-04 MORPHIN2 1.35E-04
METHDON2 7.30E-05 halflag 1.02E-04 iroxyage 1.15E-04 txilalev 1.28E-04
MORPHIN2 7.11E-05 irlsdage 9.57E-05 irpcpage 1.11E-04 oxyflag 1.24E-04
benzos 7.02E-05 otdgnedl 9.37E-05 irhalage 1.11E-04 DILAUD2 1.08E-04
irlsdage 6.17E-05 OXYCODP2 6.94E-05 txilalev 9.57E-05 lsdflag 9.08E-05
irtrnage 5.56E-05 MESC2 6.67E-05 halflag 8.28E-05 irhalage 8.72E-05
trqflag 5.41E-05 irhalage 5.92E-05 pcpflag 7.54E-05 irlsdage 8.56E-05
MESC2 5.25E-05 iroxyage 5.47E-05 irecsage 7.49E-05 pcpflag 8.53E-05
PSILCY2 5.21E-05 oxyflag 5.38E-05 PSILCY2 6.94E-05 irtrnage 8.49E-05
2003-2005 2006-2008 2009-2011 2012-2014
Adult Variables and Importance Scores


















8 Adult 2003-2005 111,561 35% 10 300 6.04 0.2 0.6063 0.4884 0.9707 0.4741
9 Adult 2006-2008 111,561 35% 10 300 5.89 0.2 0.6020 0.4810 0.9719 0.4675
10 Adult 2009-2011 111,561 35% 10 300 6.10 0.2 0.6231 0.4570 0.9685 0.4426
11 Adult 2012-2014 111,561 35% 10 300 6.22 0.2 0.6522 0.5201 0.9740 0.5066
Tuning Parameters
Figure 13: Tuning Parameters for Trials 8-11 
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Using training data of 100% of the dataset and PCA() tuning parameters of mtry = 20 and ntree = 
300, we identified the top twenty variables, ranked by importance, for the youth datasets (See Fig 
15). 
The complete set of adult and youth variables, with their descriptions, is listed in Appendix A. 
One Last Imputation 
 There were several composite variables that arose in the important variable lists.  For 
example, the variable “halflag” is a flag that represents the use of LSD, PCP, ecstasy, psilocybin, 
and other hallucinogens.  Leaving “halflag” in the list without modification makes drugs such as 
ecstasy, whose flag variable “ecsflag” is also an important variable, get double counted.  To 


















12 Youth 2003-2005 55,176 35% 10 300 1.14 0.2 0.0407 0.0000 0.9773 0.0000
13 Youth 2006-2008 55,176 35% 10 300 59.81 0.2 0.2409 0.0725 0.9831 0.0713
14 Youth 2003-2005 55,176 50% 10 300 1.18 0.2 0.2420 0.1328 0.9744 0.1294
15 Youth 2003-2005 55,176 100% 20 300 1.40 0.2 N/A 0.6079 0.9917 0.6029
16 Youth 2006-2008 55,176 100% 20 300 1.17 0.2 N/A 0.6341 0.9938 0.6301
17 Youth 2009-2011 55,176 100% 20 300 1.20 0.2 N/A 0.5997 0.9920 0.5949
18 Youth 2011-2014 55,176 100% 20 300 1.02 0.2 N/A 0.4490 0.9920 0.4454
Tuning Parameters
Figure 14: Tuning Parameters for Trials 12-18 
Figure 145: Youth Important Variables by Time Period 
Beattie | 28  
 
the composite variables.  In the case of “halflag”, we created “otherhal”, which represented the 
use of hallucinogens other than LSD, ecstasy, PCP, psilocybin, and mescaline.  Similarly, we 
created the flags “otherstim” for stimulants other than methamphetamine, “otherpain” for pain 
killers other than morphine, and “onlyoxycod” for oxycodone derivatives other than OxyContin.  
If we had perfect knowledge of the dataset, we could have performed these splits prior to PCA 
and random forest modelling.  However, one of the strengths of our approach is that it identifies 
factors worthy of close inspection from an otherwise unwieldy dataset. 
Interpretation of Variable Selection 
Although the NSDUH dataset contains a great many variables across many different 
aspects of a respondent’s experiences and environment, the variables that are most important in 
identifying correlation to heroin use fall into six categories for adults, and seven for youths (See 
Fig. 16).   
The first and largest category of important variables is the set of flags indicating whether 
a respondent has ever used a specific drug.  Tobacco, alcohol, and marijuana did not appear in 
this list, even for youths, whose experience with a wide variety of drugs would be expected to be 
narrower than for adults.  As shown in Fig. 17 below, we found that heroin users also used many 
of the drugs found in our most important variable list.  However, only users of certain drugs had 
a high rate of heroin use.  For example, over 45% of OxyContin and methadone users also used 
heroin, while less than 10% of hallucinogen and oxycodone (excluding OxyContin) users did. 
The second category is access to heroin.  Did the respondent find heroin easy to acquire?  
The third is perceived risk of heroin use.  Did the user find heroin risky to use regularly?  If not, 
did she find it risky to try?   
The fourth set is age-of-first-use (AFU) variables for specific drugs.  While the NSDUH 
does not include AFU variables for all drugs, it covers some commonly abused ones, including 
cocaine, crack, and methamphetamine.8  Inclusion of AFU drugs in our study does not explain 
which drugs were used before heroin, but other studies have compared AFU values between 
                                                 
8 It is interesting to note that AFU variables for tobacco, alcohol, and marijuana, which are often described as 
“gateway” drugs, were not selected by our methods.   
Figure 16: Variable Categories 
Prior Substance Abuse Treatment




Perceived Risk of Heroin Use
Age of First Use of Specific Drugs
Needle Use
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heroin and other drugs (Jones, 2013).  Our focus is instead limited to the relation between AFU 
for various drugs and any heroin use, whether it occurred before or after those drugs. 
The fifth category was a set of variables that indicated that the respondent had used 
needles to inject cocaine, methamphetamine, or other drugs.  The sixth category was a flag 
indicating if a respondent had prior treatment for substance abuse.   
The seventh category of variables applies only to youths.  Frequency of use variables 
were important across each block of years, but especially in the 2012-2014 dataset.  These 
variables fell into two sub-categories.  The first was how often a respondent used a given drug in 
the past year.  The second was whether a respondent had used a given drug even once in the past 
year.  These variables overlap – if the flag for use at least once is positive, the frequency of use 
flag must be at least one.  This fact allowed us to consider only the variable for how often a 
respondent used the drug. 
 
Model Construction 
 Given that the largest category of variables available to the model are those that are flags 
for specific drugs, we decided to insulate their effects by creating a two-phase model.  The first 
phase of the model was to predict heroin usage as a function of individual drug use flags.  This 
phase allows us to do two things.  First, it enables us to identify the drugs that are most 
associated with heroin for a block of time.  In this analysis we refer to these drugs as critical 
drugs.  Second, it shows us how the strength of correlation between other drugs and heroin has 
evolved over time.  The general form for this phase is: 
 
Drug






% of Heroin 
Users That Used 
Drug
% of Drug Users 
That Used 
Heroin
Methadone 4,927 2,566 6,710 27.66% 52.08%
Oxycontin 8,503 3,875 5,401 41.77% 45.57%
Crack 13,897 5,739 3,537 61.87% 41.30%
Morphine 7,778 3,168 6,108 34.15% 40.73%
PCP 9,304 3,080 6,196 33.20% 33.10%
Mescaline 10,252 2,740 6,536 29.54% 26.73%
Meth, Desoxy, 19,366 3,681 5,595 39.68% 19.01%
Codeine 18,940 3,559 5,717 38.37% 18.79%
Methamphetamine 25,150 4,397 4,879 47.40% 17.48%
Oxycodone Products 36,374 5,383 3,120 63.31% 14.80%
LSD 43,702 6,406 2,870 69.06% 14.66%
Ecstasy 40,876 5,359 3,917 57.77% 13.11%
Benzodiazeprine 46,881 6,006 3,270 64.75% 12.81%
Psilocybin 47,162 6,008 3,268 64.77% 12.74%
Cocaine 69,124 8,521 755 91.86% 12.33%
Tranquilizers 50,362 6,125 3,151 66.03% 12.16%
Stimulants 48,706 5,739 3,537 61.87% 11.78%
Hallucinogens 84,361 8,082 1,194 87.13% 9.58%
Oxycodone Only 21,080 1,508 7,768 16.26% 7.15%
Figure 17: Other Drug Use by Heroin Users 
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ℎ𝑒𝑟𝑜𝑖𝑛 𝑢𝑠𝑒𝑖 = 𝑓(𝑙𝑖𝑛(𝑢𝑠𝑒 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑗)) 
  𝑖 ∈ {𝑎𝑙𝑙 𝑟𝑒𝑠𝑝𝑜𝑛𝑑𝑒𝑛𝑡𝑠}, 𝑗 ∈ {𝑑𝑟𝑢𝑔𝑠 𝑖𝑑𝑒𝑛𝑡𝑖𝑓𝑖𝑒𝑑 𝑏𝑦 𝑟𝑎𝑛𝑑𝑜𝑚 𝑓𝑜𝑟𝑒𝑠𝑡 𝑚𝑜𝑑𝑒𝑙} 
 The critical drugs identified in Phase One dictate the structure of Phase Two, which 
focuses on how a respondent used those critical drugs.  Phase Two focuses only on use of the 
critical drugs and ignores use of non-critical drugs.  It focuses on critical drugs by considering 
how a respondent used those drugs.  In Phase Two, the behaviors we considered were:  how 
many critical drugs did a respondent use, did the respondent use needles to administer drugs, 
what was the minimum age of first use for the critical drugs, had the respondent received 
treatment for substance abuse, what was the respondent’s perceived risk of heroin use, how easy 
was it for the respondent to obtain heroin, and how frequently did the respondent use critical 
drugs (youths only).  The general form of this phase is: 
ℎ𝑒𝑟𝑜𝑖𝑛 𝑢𝑠𝑒𝑘 = 𝑓(𝑙𝑖𝑛(𝑝𝑜𝑙𝑦𝑎𝑏𝑢𝑠𝑒, 𝑛𝑒𝑒𝑑𝑙𝑒, 𝑚𝑖𝑛 𝐴𝐹𝑈, 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡, 𝑟𝑖𝑠𝑘, 𝑎𝑐𝑐𝑒𝑠𝑠, 𝑓𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦)) 
𝑘 ∈ {𝑢𝑠𝑒𝑟𝑠 𝑜𝑓 𝑐𝑟𝑖𝑡𝑖𝑐𝑎𝑙 𝑑𝑟𝑢𝑔𝑠} 
Our model will not be able to absolutely define heroin use as a linear combination of 
predictors.  Because the NSDUH survey describes human behavior, it is inherently 
indeterminate.  No combination of factors will absolutely dictate the actions of all respondents.  
Instead, the predictors combine to define the probability of heroin use.  We consider the 
following definition: 
γi = heroin use by respondent i 
γi ∈ {0,1} 
We assume the distribution of γ, a dichotomous value that indicates the respondent has used 
heroin, can be described by the Bernoulli function with mean μ: 
γi ~ Bernoulli(𝜇) 
0 ≤ μ ≤ 1 
In this case, where γ𝑖 is either 0 or 1, 𝜇 = P(γi = 1).  The parameter 𝜇 is defined by a linear 
combination of the predictor variables we identified in prior sections.  The function that maps the 
predictors to 𝜇 is known as the inverse link function.  It must have an asymptote at 0 when the 
combination of predictors is increasingly negative, and it must have an asymptote at 1 when the 
combination of predictors is increasingly large.  A commonly used inverse link function for this 
situation is the logistic function (Kruschke, 2015c): 




The inverse of the logistic function is the logit function: 
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To link the linear combination of predictors, 𝑙𝑖𝑛(𝑿), back to μ, we use the logit function: 
𝑙𝑜𝑔𝑖𝑡(𝜇) = 𝑙𝑜𝑔 (
𝜇
1 − 𝜇
) = 𝑙𝑜𝑔 (
𝑃(γ𝑖 = 1)
𝑃(γ𝑖 = 0)




 is known as the odds that γ𝑖 = 1.  Note that unlike a probability, which 
ranges from 0 to 1, odds ranges from 0 to ∞.  It is common to describe the change in likely 
outcome between two scenarios of factors by comparing their odds via an odds ratio: 
𝑂𝑅𝑥𝑗=1 =
𝑜𝑑𝑑𝑠(γ𝑖 = 1|𝑥𝑗 = 1)
𝑜𝑑𝑑𝑠(γ𝑖 = 1|𝑥𝑗 = 0)
 
If 𝑂𝑅𝑥𝑗=1 > 𝑂𝑅𝑥𝑘=1, we conclude that variable 𝑥𝑗 more closely predicts a positive outcome for 
γ𝑖 than does variable 𝑥𝑘.   
We define our two-phase model by substituting its predictors for 𝑿.  Phase 1 thus 
becomes: 
PHASE 1:                    γi~Bernoulli(𝜇1), logit(𝜇1) = 𝛽10 + ∑ ω𝑗𝑑𝑗
𝑗∈D1
    (Eq. 1) 
and Phase 2 becomes: 





• 𝛽10 , 𝛽20 , 𝝎, 𝛂, are constants 
• 𝑖 ∈ {𝑎𝑙𝑙 𝑟𝑒𝑠𝑝𝑜𝑛𝑑𝑒𝑛𝑡𝑠}, 𝑘 ∈ {𝑢𝑠𝑒𝑟𝑠 𝑜𝑓 𝑐𝑟𝑖𝑡𝑖𝑐𝑎𝑙 𝑑𝑟𝑢𝑔𝑠} 
• 𝑑𝑗 = any use of jth drug 
• 𝐷1 = {𝑎𝑙𝑙 𝑑𝑟𝑢𝑔𝑠} 
• 𝑔1= number of drugs used among the critical drug set (polyabuse) 
• 𝑔2= needle use flag 
• 𝑔3 = minimum age of first use of a critical drug 
• 𝑔4 = prior treatment use flag 
• 𝑔5 = perceived risk of heroin use (2=no risk of regular use, 1=no risk of occasional use, 
0=otherwise) 
• 𝑔6 = access to heroin (1=easy access, 0=otherwise) 
• 𝑔7 = frequency of use of cocaine, hallucinogens, and methamphetamine.
9 
                                                 
9 𝑔7 is used in the youth model only 
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Reducing Autocorrelation via Normalization 
 𝑔2 is an example of a dichotomous parameter – it can only have the values 1 or 0.  𝑔1 is a 
range parameter – it can be equal to any integer between 1 and the number of critical drugs.  We 
must normalize the range parameters so that their values are distributed such that the mean of a 
normalized range parameter becomes 0.  This is done to reduce autocorrelation in MCMC 





Where 𝑧𝑥 is the normalized variable corresponding to x, and 𝑠𝑥 is the standard deviation of x.  
When we normalize the range variables in our model, the linear function in the second phase 
becomes: 
𝑙𝑜𝑔𝑖𝑡(𝜇2) = ζ0 + ζ1𝑧𝑔1 + α2𝑔2 + ζ3𝑧𝑔3 + α4𝑔4 + ζ5𝑧𝑔5 + α6𝑔6 + ζ7𝑧𝑔7    (Eq. 3) 
 We will run the second phase of the model using Eq. 3.  However, we wish to be able to 
use the model on the original values of the range parameters, not on their normalized values.  We 
can convert the normalized parameters ζ0, ζ1, ζ3, ζ5, ζ7 back to the non-normalized parameters as 
follows: 


























 The set of parameters β10 , β20 , 𝝎, 𝜶, 𝝇 are not deterministic – our model cannot calculate 
with 100% certainty their values.  Instead, each parameter is subject to a distribution of its own.  
The remainder of our analysis focused on the calculation of these distributions, which in turn 
determine the distribution of 𝜇1, 𝜇2, the parameters that determine the distribution of heroin users 
when given a set of values for the predictive variables from the dataset.  In the following 
sections, we will describe our methods using Bayesian methods, solve the model, and interpret 
its outcome. 
Bayes Rule 
 Each of the parameters of our model, β10 , β20 , 𝝎, 𝜶, 𝝇, has a distribution.  If the model is 
accurate, then it will accurately predict the number of heroin users in the NSDUH dataset.  Said 
another way, the correct distributions of our parameters will maximize the likelihood that we 
observe model predictions that match the NSDUH dataset.10  Determining these distributions can 
be done via Bayesian analysis.  We will briefly review Bayes Rule and describe its relationship 
to our model. 
                                                 
10 The following discussion on Bayes Rule is drawn from (Kruschke, 2015a) 
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 Bayes Rule is easily derived from the definition of conditional probabilities.  Let θ 






which can be rewritten as: 
𝑝(𝜃, 𝐷) = 𝑝(𝜃|𝐷)𝑝(𝐷) 
It is also true that 𝑝(𝜃, 𝐷) = 𝑝(𝐷|𝜃)𝑝(𝜃).  Combining these two equations, we see that: 
𝑝(𝜃|𝐷)𝑝(𝐷) = 𝑝(𝐷|𝜃)𝑝(𝜃) 





In Bayes Rule, 𝑝(θ|𝐷) is known as the posterior distribution for the parameter θ.  
𝑝(𝐷|θ) is the likelihood of the data given a value for the parameter θ.  𝑝(θ) is the prior 
distribution for the parameter θ.  𝑝(𝐷) is known as the evidence.  Bayes Rule says that the 
posterior distribution of a parameter when given a set of data is equal to our prior belief about the 
distribution of that parameter, multiplied by the likelihood of the data we see for that parameter, 
divided by the evidence.  If we define the probability of the data as a conditional probability 





where θ∗ indicates the entire range of parameter values, distinct from a single parameter value 
under consideration.11   
The Importance of the Prior Distribution 
 In Bayesian statistics, determining the prior distribution is critically important.  The data 
that we see in an experiment will modify, not replace, our belief in the prior distribution.  If our 
assumption of a prior distribution is inaccurate, the posterior distribution will most likely be 
inaccurate as well.  Without any prior knowledge, we can set uninformed priors.  An example of 
an uninformed prior is the normal distribution with a mean of zero.  Most studies of medical 
data, because they are not Bayesian, are similar to a Bayesian analysis with uninformed priors.  
However, an uninformed prior can be invalid.  In our case, we know from many studies that 
                                                 
11 For the remainder of this discussion, we will consider Phase One of our model.  The concepts described below 
apply equally to Phase Two. 
Beattie | 34  
 
OxyContin abuse is correlated with heroin use.  We argue that we must take that knowledge into 
account with an informed prior.  Our approach, because it allows for recognition of previous 
studies via informed priors, is a better way to study medical data than by simple null hypothesis 
testing. 
Bayes Rule and the Model Parameters 
 Recall that in Phase 1, the probability that a respondent has used heroin is distributed as a 
Bernoulli trial with parameter 𝜇1, which in turn is a linear function of parameters 𝛃𝟏𝟎, 𝛚, each of 
which has their own distribution that we assume to be independent of the other parameters.  We 
define the data for our model as the set of respondents’ use of heroin:  D = {γ𝑖},   𝑖  ∈







𝑝(𝛄|𝛃𝟏𝟎 , 𝛚)𝑝(𝛃𝟏𝟎 , 𝛚)
𝑝(𝛄)
                      (Eq. 4) 




For our model, 𝑝(𝛃𝟏𝟎 , 𝛚) is the set of prior distributions for our parameters.  𝑝(𝛄|𝛃𝟏𝟎 , 𝛚) is the 
likelihood of heroin use given a set of our parameters.  𝑝(γ) is the evidence for our data, and 
𝑝(𝛃𝟏𝟎 , 𝛚|𝛄) is the posterior distribution of our parameters.  Finding the set of posterior 
distributions is the goal of our model. 
Monte Carlo-Markov Chain Methods to Estimate Posterior Distributions 
 Evaluation of the compound integral for 𝑝(𝛄) is extremely difficult.  To determine the 
posterior distributions for the model parameters, we must use approximations using Monte 
Carlo-Markov Chain (MCMC) methods12.  MCMC methods approximate the posterior 
distribution of a parameter (or set of parameters) by generating a sequence of values for the 
parameter.  Values are added to the sequence in a random-walk manner dictated by a 
combination of the prior probability of the value and the likelihood of the data as a function of 
that prior value.  Said another way, the MCMC methods select a set of values from the prior 
distributions that are likely to generate the data seen by the researcher. 
                                                 
12 The following discussion is based upon (Kruschke, 2015b) 
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Gibbs Sampling 
For each iteration of the MCMC random walk, we select one of the following parameters 
to consider for change:  β10; 𝜔𝑖, 𝑖 ∈ 𝐷1.  We are therefore selecting one of 1 + |𝐷1| total 
variables to consider for change.  To generate enough values of each parameter to estimate all 
posterior distributions, we iterate through each parameter in turn.  Within an iteration we then 
generate a proposed value for the considered parameter based upon its distribution conditioned 
against the data and the fixed values of the other parameters.  We then proceed to the next 
iteration by considering the next parameter.  We stop the random walk when we reach N, the 
number of iterations dictated by the researcher.  Using the parameters from our model, we 
describe Gibbs sampling as follows: 
1) Define 𝛉 as an ordered sequence of the parameters for our model, where θ0 = β0,  θ1 =
𝜔1,  θ2 = 𝜔2, . . . , θ1+|𝐷1| = 𝜔|𝐷1|.  Set 𝑖 = 0. 
2) Select a value for θ𝑖 according to the distribution 𝑝(θ𝑖|{θ𝑗≠𝑖}, 𝛄) and add to the set θ𝑖 =




3) Set 𝑖 = 𝑖 + 1 
4) Repeat steps 2-3 until 𝑖 = 𝑁 + 1 
Gibbs Sampling works because at each step we are generating a parameter value directly 
from the posterior conditional distribution for that parameter.  The posterior conditional 
distribution is set by the combination of the likelihood of the data given the parameter value and 
the prior probability of that parameter value.  The set of all values we generate for a particular 
parameter is thus a representation of the posterior distribution of that particular parameter. 
In our analysis, we implemented Gibbs Sampling by using the JAGS software package, 
which stands for “Just Another Gibbs Sampler” (Plummer, 2003).  JAGS automatically builds 
MCMC samplers for hierarchical Bayesian models.  JAGS reduces the complexity of 
implementing Gibbs Sampling and allows the researcher to focus on more interesting areas of 
concern, such as selecting the prior distributions for model parameters.  To speed up the 
performance of our model, we used the runjags package (Denwood, 2016), which optimizes 
JAGS by making use of multiple CPUs.  We also used previously written routines to provide 
graphical output for the sampler and script templates for our models (Kruschke, 2015d). 
Setting the Priors 
 Setting the priors was a critical step in our analysis.  Unlike many studies of medical data, 
our model would build upon previous knowledge by incorporating the findings of other studies 
as prior probabilities for our model parameters.  To set the prior distributions for our model 
parameters, we performed a literature search in which we looked for studies that found 
significant correlation between any member of our factor set and heroin use.  Our factor set was 
the group of variables indicated by our random forest analysis as important.  We sought to 
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maintain the concept of “prior” knowledge by considering only studies that did not use the 
NSDUH datasets.   
We first considered a concept that has received a great deal of attention -- the link 
between nonmedical prescription opioid (NPO) abuse and heroin use.  Progression from NPO 
abuse, particularly OxyContin, to heroin involves crossing thresholds of stigma associated with 
heroin as the cost of NPOs increases (Mars, Bourgois, Karandinos, Montero, & Ciccarone, 
2014).  One quantitative study found that 70% to 80% of heroin-dependent respondents used an 
NPO as their first abused opioid, and that heroin abuse rose as a new, abuse resistant formula of 
OxyContin was released (Cicero et al., 2014).  Another study found that young intravenous drug 
users frequently initiated NPO use and transitioned to heroin.  The same study found that heroin 
users initiated or continued NPO abuse, particularly that of OxyContin, for a variety of reasons, 
including easier access or lower price than heroin, to boost the effects of heroin use, and to avoid 
heroin withdrawal symptoms (Lankenau et al., 2012).  From these prior studies, we can conclude 
that there is a probably strong correlation between OxyContin use and heroin.  Furthermore, 
respondents in the studies frequently mention OxyContin, but don’t cite other oxycodone 
formulations as regularly.  For this reason, we don’t assume a link between non-OxyContin 
oxycodone and heroin. 
Unsurprisingly, easy access to heroin was found to be correlated to heroin use (Maher et 
al., 2007).  Some studies found a link between low age-of-first-use (AFU) of various drugs and 
eventual heroin use but did not quantify a linear relationship between them (Kandel, et al., 1992; 
Pugatch et al., 2001).  The prevalence of cocaine abuse among heroin users was high, and 50% 
of intravenous cocaine users were found to also use heroin (Leri, Bruneau, & Stewart, 2003).  
We also found studies that identified links between heroin and crack (Beswick et al., 2001; Mc 
Bride et al., 1992) and between heroin and dilaudid (McBride, 1980).  Multiple studies indicated 
a strong correlation between intravenous use of other drugs and heroin use (Leri et al., 2003; 
Rhodes, Briggs, Kimber, Jones, & Holloway, 2007).  For the remainder of the factors, we either 
found no evidence in the literature for a link to heroin use or inconclusive evidence.  The table in 
Appendix B summarizes the findings of our search. 
Translating the results of a literature search into probability distributions for priors is at 
the discretion of the researcher and is therefore subject to scrutiny.  Fortunately, Greenland has 
studied this problem extensively and has provided guidelines for researchers who wish to apply 
Bayesian techniques to medical data (Greenland, 2000, 2001, 2006, 2007).13 
 The priors for a Bayesian analysis should reflect results from previous studies in order to 
seem reasonable or credible.  If true frequency distributions exist and are known for parameters, 
those should be used for the prior distributions.  And while they aren’t exact, the use of estimated 
priors is still better than relying on the datasets in the current study alone.  Greenland 
                                                 
13 The following discussion on how to set priors summarizes Greenland’s approach. 
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recommends thinking of priors as making bets, which are commonly expressed as odds ratios.  
An odds ratio of 1 represents even odds – we don’t know whether a factor will increase or 
decrease the chance of a positive outcome.  An odds ratio of less than 1 means that the presence 
of a factor will reduce the chance of a positive outcome, and an OR of greater than 1 means the 
factor will increase the chance. 
 Bets are uncertain things.  Not only do we guess at an odds ratio, we have varying 
degrees of uncertainty regarding that guess.  We can express this uncertainty like this:  “We are 
95% certain that the odds ratio for the correlation between LSD and heroin use is between ¼ and 
4.”  As our certainty of an OR increases, the range between the high and low estimates of the OR 
shrinks.  The more certain that we are that there is a positive effect of a factor, the greater the 
bottom and top of the range become. 
 Determining a shape for the probability distribution function (pdf) of a parameter is 
particularly difficult.  Sometimes the attributes of a factor can help determine the pdf.  For 
example, if a factor can only have a positive impact on an outcome, we can choose the beta 
distribution, which begins at 0.  In the absence of such information, we should stick with a less 
informative prior, such as the normal distribution, which can be positive or negative.  In our 
analysis, we had no guiding information or factor attributes that would point to a specific pdf for 
any prior.  We assumed that all our priors were normally distributed. 
Many of the studies we encountered in our literature search consisted of surveys of a 
small number of respondents.  When compared to the scope of the NSDUH dataset, they were 
extremely small.  The findings from these studies therefore provide us with what Greenland 
describes as subjective priors.  In such cases, we can use three categories of factors commonly 
used by clinicians: 
• Uncertain direction:  mean OR of 1, 95% certainty of a range between ¼ and 4 
• Probably positive:  mean OR of 2, 95% certainty of a range between ½ and 8 
• Probably strong:  mean OR of 4, 95% certainty of a range between 1 and 16 
As we mentioned earlier, a regression parameter is equal to the logarithm of an odds ratio.  The 
mean value for a parameter is simply 𝛽?̅? = 𝑙𝑛(𝑂𝑅𝑖).  The 95% confidence interval for a 
parameter is equal to 𝛽?̅? ± 1.96σ
1/2, where σ is the variance of the parameter.  Using these 
definitions, we can convert Greenland’s subjective bets into probability distributions of the form 
Normal(mean, variance). 
• Uncertain direction:  Normal (0, 0.5) 
• Probably positive:  Normal (0.6931, 0.5) 
• Probably negative:  Normal (-0.6931, 0.5) 
• Probably strongly positive:  Normal (1.396, 0.5) 
• Probably strongly negative:  Normal (-1.396, 0.5) 
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We can now set the prior distributions for the parameters associated with the factors in our model 
(See Fig. 18).  All other parameters were set with uninformative priors of Normal (0, 0.5). 
Running the Gibbs Sampling Model 
 Phase One of Gibbs sampling involved considering nineteen parameters from datasets of 
up to 120,000 observations.  Despite using runjags on a powerful virtual machine,14 we had to 
limit ourselves to random samples of the model so that it would complete.  Because heroin users 
represent a small portion of the respondents of the NSDUH dataset, we tried to use as large a 
sample as possible.  We ran Phase One on the 2003-2005 adult dataset with three different sizes 
of sample, 25% of the total, 35%, and 50%,15 to determine an appropriate sample size.  We found 
that the 50% sample ran in between eight to twelve hours.  We were unable to calculate DIC 
samples for the model, which limited our ability to compare different versions of Phase One.  
However, in Phase One we were focusing on identifying the relative strength of correlations 
between factors and heroin use, and not a definitive prediction of heroin use.  We therefore opted 
to focus on the largest sample, the 50% sample, and concede the calculation of DIC samples in 
our analysis.  For consistency, we chose to also use 50% of the adult datasets for Phase Two of 
the model.  Because the number of youth heroin users is small, and because the youth dataset is 
smaller, we used 70% of the dataset for Phases One and Two.  This allowed us to maximize the 
number of observations in the model while still preserving a holdout sample for model 
validation. 
 When conducting a Bayesian analysis, we can reject the null hypothesis when a value for 
a parameter that corresponds to the null is outside of the highest density interval (HDI).  The 
HDI commonly consists of 95% of the distribution of a parameter.  In our model, we have 
assumed that all the parameters are normally distributed.  If the 95% interval of a parameter’s 
distribution includes 0, the null is within the HDI.  In Phase One, we considered nineteen drugs 
                                                 
14 An 8 CPU Linux machine with 16GB of RAM running on Microsoft Azure 
15 We were unable to get the model to complete on 100% of the dataset.  Nor were we able to compute DIC samples 







Prior Distribution:  
Normal (mean, 
rdifher Heroin fairly or very easy to obtain alpha6 N Probably Positive Normal (0.6931, 0.5)




cocflag Cocaine - ever used omega2 N Probably Positive Normal (0.6931, 0.5)
crkflag Crack - ever used omega6 N Probably Positive Normal (0.6931, 0.5)
DILAUD2 Dilaudid - ever used omega7 N Probably Positive Normal (0.6931, 0.5)
















Flag for multiple high risk drug use (equal 
to number of drugs)
zeta1 Y Probably Positive Normal (0.6931, 0.5)
Figure 18: Prior Distributions 
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for inclusion in the critical drug set.  We dropped any drug 𝑑𝑖 whose distribution of parameter ω𝑖 
was found to include 0 in the HDI from the list.  In Phase Two, any factor 𝑔𝑖 whose distribution 
of parameter α𝑖 included 0 was found to not correlate with heroin use.  In both Phases, we sought 
to find non-null parameters, the relative strength of the parameters, and changes in these 
outcomes over time. 
A Note on Odds Ratios 
 The parameter mean values and HDIs from Gibbs sampling directly indicate the strength 
of the factors in our model, but we have calculated odds ratios (OR) for consistency with other 
studies.  This is because medical and epidemiological studies often express the strength of 
predictive factors this way.  It is important to point out that an odds ratio is exactly that – a ratio.  
We must have something in the numerator and the denominator.  In Phase One, the OR is 
simple:  the numerator indicates the odds of heroin use when the respondent has also used drug 
𝑑𝑖.  The denominator indicates the odds of heroin use when the respondent has not used any 
other drug 𝑑𝑖 , 𝑖 ∈ 𝐷1: 
𝑂𝑅𝑖 =
𝑜𝑑𝑑𝑠(𝛾 = 1|𝑑𝑖 = 1, 𝑑𝑗 = 0, 𝑖 ≠ 𝑗)






In Phase Two, things get more complicated.  The factors are not just dichotomous flags, 
they include ranges:  polyabuse of drugs (𝑔𝑖 ≥ 1), minimum age of first use of a critical drug 
(𝑔3 ≤ 99), and perceived risk of heroin abuse (𝑔5 ∈ {0,1,2}).  Fortunately, proper consideration 
of the factors in the numerator and denominator of the OR will cancel out all but the factor of 
interest.  To illustrate this, suppose we want to calculate the OR for age of first use.  We begin by 
creating a base case for the denominator.  We define this case as a construction of likely values 
for each of the factors:  no needle use, heroin is difficult to get, the respondent perceives high 
risk with heroin use, he has never received prior treatment for substance abuse, he has only used 
one critical drug, and his first use of a critical drug occurred at age 19.  In the numerator we 
place a case identical to the base case, except the age of first use occurred at value a, which is not 





In the case where 𝑎 = 20, 𝑂𝑅2,𝑎=20 = 𝑒
β5 .  When 𝑎 = 21, 𝑂𝑅2,𝑎=21 = 𝑒
2β5 = 𝑂𝑅2,𝑎=20
2 .  
While we can calculate odds ratios for range values, we must apply them differently when 
considering values more than one unit from the base case for the factor.   
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In general, the method we used to illustrate odds ratios for a range variable can be extended 
to comparing any two combinations of factors.  For example, suppose we wish to estimate how 
much more likely heroin use by respondent A is than heroin use by respondent B (See Fig. 19). 











Knowing the values for the parameters of the model thus gives us a very powerful means of 
estimating how different behaviors can increase the likelihood of corresponding heroin use. 
Results 
 In this section, we discuss the results from the MCMC analysis for the Adult and Youth 
models.  For each model, we will show which drugs were determined critical – those whose 
parameters had null values outside of the high-density interval (HDI).  We will also show 
changes in critical drugs over time and in their relative impacts by comparing their odds ratios.  
We will then discuss how usage patterns and respondent attributes affect the likelihood of heroin 
use by users of critical drugs. 
Adult Critical Drug Analysis (Model Phase One) 
 The parameter values, HDIs, and odds ratios for the adult model are shown in Appendix 
C.  We will discuss the results from 2003-2005 to illustrate results interpretation for all the 
iterations of the analysis.  
Description A B
Polyabuse (number of critical drugs used) 2 4
Ever used needle to inject any drug N Y
Minimum AFU for any critical drug 18 16
Ever received treatment for substance abuse N Y
Perceived risk of heroin use High High
Easy to access heroin Y Y
Respondent A
Figure 19: Comparing Two Potential Heroin Users 
Beattie | 41  
 
As we see in Fig. 20, 11 of the 19 drugs under consideration were critical.  Interestingly, 
OxyContin, which our literature search indicated was closely linked to heroin use, was not 
critical.  Despite that fact that we set a prior for OxyContin to Probably Strongly Positive, the 
data from this period shifted the distribution towards the null.  The drug most closely correlated 
with heroin usage was cocaine.  Cocaine users are almost 16 times more likely than non-cocaine 
users to use heroin.  Crack was the second most strongly correlated drug.  It is possible that these 
two drugs are most strongly linked to heroin by the action of “speedballing”.  In speedballing, 
users seek to reinforce the effects of both cocaine/crack and heroin by using them together (Leri 
et al., 2003; McBride et al., 1992; Rhodes et al., 2007).  Dilaudid, the third most strongly linked 
drug, is less common in current literature, but was linked to heroin use in the past (McBride, 
1980).  It is possible that dual dilaudid/heroin users are older, and this could be determined 
through further analysis of the NSDUH data.  Methadone is often a treatment for recovering 
heroin addicts, but the NSDUH study asks specifically about methadone abuse.  When we see it 
here as a correlate to heroin use, we are seeing the link between illicit methadone use and heroin 
use. 
One of the most powerful attributes of MCMC is the ability to examine the distributions 
of the model parameters.  We will illustrate this attribute for this run of the model here.  We 
compare the distributions for the parameters associated with cocaine (ω2) and OxyContin (ω16) 
in Fig. 21. 
Figure 20: Adult Critical Drugs 2003-2005 (nulls in red italic) 
Drug Mean SD 2.50% 97.50% OR
Intercept -7.0472 0.1744 -7.4053 -6.7184 1.0000
Cocaine 2.7466 0.2048 2.3550 3.1583 15.5895
Crack 1.5521 0.1004 1.3564 1.7495 4.7213
Dilaudid 0.8575 0.2124 0.4398 1.2725 2.3573
Methadone 0.8470 0.1639 0.5251 1.1670 2.3326
PCP 0.7317 0.1109 0.5148 0.9493 2.0785
Tranquilizers 0.7285 0.2966 0.1408 1.3035 2.0721
Mescaline 0.6997 0.1126 0.4775 0.9201 2.0131
LSD 0.6831 0.1313 0.4246 0.9377 1.9800
Morphine 0.6023 0.2064 0.1959 1.0045 1.8262
Oxycodone (not OxyContin) 0.3053 0.1375 -0.0360 0.5756 1.3571
Ecstasy 0.2997 0.1073 0.0891 0.5090 1.3495
OxyContin 0.2856 0.1640 -0.0349 0.6058 1.3306
Other Pain Killers 0.2570 0.1468 -0.0349 0.5425 1.2931
Codeine 0.0120 0.1356 -0.2543 0.2784 1.0121
Psilocybin -0.0413 0.1189 -0.2738 0.1917 0.9595
Other Stimulants -0.0705 0.1540 -0.3755 0.2264 0.9319
Other Hallucinogens -0.1996 0.6916 -1.6655 1.0316 0.8190
Benzos -0.2659 0.2930 -0.8311 0.3170 0.7665
Methamphetamine -0.3371 0.1153 -0.5638 -0.1120 0.7139
Adult Years 2003-2005:  50% Sample (Informed Prior)
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 In the fourth quadrant charts, we see that the parameters follow the normal distribution, 
as they should since we set the priors that way.  The HDI for ω2 is well above 0, the null value.  
In contrast the HDI for ω16 includes 0.  The model execution wasn’t perfect – autocorrelation of 
ω2 approaches 0 yet doesn’t do so quickly.  Since the factors in the model are all dichotomous 
flags, normalizing them won’t reduce autocorrelation.  When we examine the cross-correlations 
for the model (Fig. 22), we see negative correlation between ω2 and the intercept 𝛽0.  It is 
possible that normalizing the intercept could reduce autocorrelation, but due to the extraordinary 
runtimes for the model (over nine hours), we elected to accept the outcomes as they are.16 
 To easily compare the changes of critical drugs across time, we ranked the drug flag 
parameters by odds ratio, with 1 being the most impactful parameter and 19 being the least (See 
Fig. 23).  Again, drugs in red are those whose HDI included 0, making them null.  Cocaine 
remains the drug with the highest odds ratios across all four time periods, and crack remains the 
                                                 
16 We also see relationships between oxycodone (no OxyContin) and OxyContin.  This could be due to use of 
multiple drugs in this category by users. 
Figure 21: Sample Adult Phase One Parameter Distributions 
Figure 22: Adult Drug Use Crosscorrelation 
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second highest.  We also see consistency among most of the low odds-ratio drugs – psilocybin 
and other hallucinogens are not positively associated with heroin use in any time period.  
  Note that we see a marked increase in the odds ratio for OxyContin.  In 2006-2008 it 
ceases to be null, and by 2012-2014 OxyContin has the third highest OR.  Because cocaine and 
crack can both be associated with simultaneous heroin use, by 2012-2014 OxyContin has 
become the independent drug with the highest association with heroin.  This finding reinforces 
what we found in the literature – non-medical prescription opioid use can lead to heroin abuse.  
OxyContin abusers are over 2.6 times as likely to use heroin as non-abusers.  Abuse of non-
OxyContin oxycodone climb to 1.7 times as likely to abuse heroin as non-abuse.  PCP had 
consistently high odds ratios across all years despite a lack of prior evidence from the literature. 
Adult Usage Pattern Analysis (Model Phase Two) 
 The parameter values, HDIs, and odds ratios for the usage pattern model are shown in 
Appendix D.  Again, we will discuss the results from 2003-2005 (Fig. 24) to illustrate results 
interpretation for all the iterations of the analysis.  Recall that for Phase Two, the respondent set 
is restricted to users of the critical (non-null) drugs identified in Phase One. 
Figure 23: Adult Drug Use Ranks and Odds Ratios (nulls in red italic) 
Drug Rank OR Rank OR Rank OR Rank OR
Cocaine 1 15.5895 1 11.8626 1 14.3677 1 11.3874
Crack 2 4.7213 2 4.3120 2 4.3479 2 3.7005
Dilaudid 3 2.3573 4 2.4495 5 1.9429 5 2.1821
Methadone 4 2.3326 8 1.6352 4 2.0846 7 1.7290
PCP 5 2.0785 3 2.6355 3 2.1977 4 2.5568
Tranquilizers 6 2.0721 18 0.9656 11 1.3386 15 0.9161
Mescaline 7 2.0131 9 1.5572 7 1.8197 11 1.5315
LSD 8 1.9800 5 1.8669 10 1.4814 12 1.4325
Morphine 9 1.8262 6 1.8551 9 1.7128 6 2.1604
Oxycodone (not OxyContin) 10 1.3571 12 1.3383 14 1.0866 8 1.7146
Ecstasy 11 1.3495 11 1.4146 8 1.7288 10 1.5827
OxyContin 12 1.3306 7 1.7323 6 1.8538 3 2.6672
Other Pain Killers 13 1.2931 14 1.0971 15 1.0820 14 1.0822
Codeine 14 1.0121 19 0.9549 17 1.0427 18 0.7766
Psilocybin 15 0.9595 16 1.0246 19 0.9363 16 0.8961
Other Stimulants 16 0.9319 17 0.9949 12 1.2570 17 0.8649
Other Hallucinogens 17 0.8190 10 1.5175 16 1.0686 19 0.4298
Benzos 18 0.7665 13 1.3366 18 1.0130 9 1.6866
Methamphetamine 19 0.7139 15 1.0367 13 1.1048 13 1.3021
Adult Ranking and Odds Ratios of Drug Use Flags (Nulls in Red Italic )
2003-2005 2006-2008 2009-2011 2012-2014




Despite having a Probably Negative prior, the Age of First Use (AFU), which is the minimum 
age that a respondent used any critical drug, is null.  In fact, the parameter for AFU, α3, is nearly 
centered on zero.  In contrast, the correlation between needle use and heroin use is strongly 
positive.  The odds ratio for the needle use parameter, α2, is 4.390.  The diagnostic plots in Fig. 
25 show that the HDI for α2 does not include zero, while the HDI for α3 does. 
 
 As shown in Fig. 26, the rankings for the usage pattern parameters are virtually 
unchanged over time.  Needle use, access to heroin, and prior substance abuse treatment strongly 
affect the probability of heroin use.  The parameter for AFU remains null for two time periods 
and then becomes correlated, but only slightly so, with heroin use. 
Figure 24: Adult Usage Pattern Factors (nulls in red italic) 
Figure 25: Sample Adult Phase Two Parameter Distributions 
Drug Mean SD 2.50% 97.50% OR
Intercept -5.5831 0.2498 -6.0731 -5.0935 1.0000
Needle Use 1.4793 0.1031 1.2776 1.6819 4.3898
Access to Heroin 1.3083 0.0816 1.1487 1.4676 3.7000
Prior Treatment 0.6782 0.0827 0.5167 0.8399 1.9703
Perceived Risk 0.6122 0.0576 0.4990 0.7252 1.8444
Polyabuse 0.5105 0.0207 0.4701 0.5514 1.6661
Age of First Use -0.0037 0.0113 -0.0261 0.0180 0.9963
Adult Years 2003-2005:  50% Sample (Informed Prior)
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Figure 26: Adult Usage Pattern Ranks and Odds Ratios 
The value of the AFU parameter for 2012-2014 is 𝛼3 = −0.0306.  Consider two respondents 
from that time period.  Respondent B began critical drug use at the age of 19, the average for all 
respondents.  Respondent A began critical drug use at the age of 16.  As we described above, we 














The odds that Respondent A uses heroin are less than 10% higher than that of Respondent B.  
We can thus drop the AFU variable from our model.  This greatly simplifies the Phase Two 
model and makes it easier to apply in practice.  In order to include AFU in the Phase Two model, 
we had to restrict the dataset to only those respondents who had used a critical drug.  By 
removing AFU, we can once again apply the model to the entire dataset.  For example, if we 
encounter a respondent who has used three critical drugs (polyabuse = 3), a model without AFU 
allows us to compare their odds of heroin use to a non-user or to a user of a non-critical drug 
such as marijuana.  When we remove AFU, the Adult Revised Phase Two Model becomes:    
ℎ𝑒𝑟𝑜𝑖𝑛 𝑢𝑠𝑒𝑗 = 𝑓(𝑙𝑖𝑛(𝑝𝑜𝑙𝑦𝑎𝑏𝑢𝑠𝑒, 𝑛𝑒𝑒𝑑𝑙𝑒, 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡, 𝑟𝑖𝑠𝑘, 𝑎𝑐𝑐𝑒𝑠𝑠)) 
𝑗 ∈ {𝑎𝑙𝑙 𝑟𝑒𝑠𝑝𝑜𝑛𝑑𝑒𝑛𝑡𝑠} 
γ𝑗~𝐵𝑒𝑟𝑛𝑜𝑢𝑙𝑙𝑖(𝜇2), 𝑙𝑜𝑔𝑖𝑡(𝜇2) = ζ0 + ζ1𝑧𝑔1 + α2𝑔2 + α4𝑔4 + ζ5𝑧𝑔5 + α6𝑔6    (𝐸𝑞. 4)  














With the removal of AFU, none of the remaining predictors are null.  When we examine the 
parameter values for the 2003-2005 dataset in Fig. 27, we see that the values for the predictors 
increase slightly as well. 
Drug Rank OR Rank OR Rank OR Rank OR
Needle Use 1 4.3898 1 5.9625 1 5.8058 1 4.8345
Access to Heroin 2 3.7000 2 2.9607 2 2.8875 2 3.3878
Prior Treatment 3 1.9703 3 2.0161 4 1.8925 3 2.2835
Perceived Risk 4 1.8444 4 1.9365 3 1.7977 4 1.9691
Polyabuse 5 1.6661 5 1.7934 5 1.7704 5 1.6172
Age of First Use 6 0.9963 6 1.0001 6 0.9728 6 0.9699
Adult Ranking and Odds Ratios of Usage Pattern Flags (Nulls in Red Italic )
2003-2005 2006-2008 2009-2011 2012-2014
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 In Fig. 28, we again see stability in the rankings of the usage pattern factors.  Needle Use 
and Access to Heroin remain the strongest correlates with heroin usage.  In the 2012-2014 
dataset, needle users were 5.61 times as likely as non-needle users to also use heroin.  Access to 
heroin also greatly increases the odds of heroin use – a respondent with easy heroin access is 
3.93 times more likely to use than somebody without access. 
 
Youth Critical Drug Use Analysis (Model Phase One) 
 The parameters for the youth (respondents under the age of 18) critical drug analysis are 
shown in Appendix F.  As we interpret this data, it is important to keep in mind that there were 
far less youth heroin users than adults.  As a result, we should expect more variability in our 
results.  We can see that there are significantly less critical drugs for youths than for adults.  
While we aren’t sure of the reason for this, we can guess that one explanation would be that 
youths simply haven’t had as much time as adults to use many drugs.  In 2003-2005, only five of 
the 19 candidate drugs were critical (Fig. 29). 
Figure 28: Revised Adult Usage Pattern Ranks and Odds Ratios 
Figure 27: Revised Adult Usage Pattern Factors 
Drug Mean SD 2.50% 97.50% OR
Intercept -6.6272 0.9081 -6.8090 -6.4524 1.0000
Needle Use 1.5487 0.1104 1.3301 1.7633 4.7053
Access to Heroin 1.2778 0.0815 1.1181 1.4374 3.5887
Prior Treatment 0.8380 0.0869 0.6670 1.0077 2.3117
Polyabuse 0.6830 0.0166 0.6508 0.7160 1.9798
Perceived Risk 0.6261 0.0586 0.5104 0.7405 1.8703
 Revised Adult Years 2003-2005:  50% Sample (Informed Prior)
Drug Rank OR Rank OR Rank OR Rank OR
Needle Use 1 4.7053 1 6.5666 1 5.5367 1 5.6062
Access to Heroin 2 3.5887 2 2.9910 2 3.0600 2 3.9318
Prior Treatment 3 2.3117 3 2.2129 4 2.1417 3 2.6977
Polyabuse 4 1.9798 4 2.1285 3 2.1572 5 1.8699
Perceived Risk 5 1.8703 5 1.7918 5 1.7522 4 2.0555
Revised Adult Ranking and Odds Ratios of Usage Pattern Flags (Nulls in Red Italic )
2003-2005 2006-2008 2009-2011 2012-2014
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 When we look at the rankings of critical drugs over time (Fig. 30), we again see a 
dramatic rise in the correlation strength of OxyContin.  In 2003-2005, it was a critical drug, but 
in the next two periods, its correlation with heroin use became negligible, only to rise again in 
2012-2014.  It is possible that the relatively high ranking of OxyContin in 2003-2005 is a 
function of the small youth heroin user cohort.  The subsequent time periods mirror the rise in 
importance of OxyContin we saw in the adult datasets.  We also see a rise in the importance of 
oxycodone and crack across the time periods. 
  
Figure 29: Youth Critical Drugs 2003-2005 (nulls in red italic) 
Drug Mean SD 2.50% 97.50% OR
Intercept -7.1958 0.2175 -7.6401 -6.7917 1.0000
Cocaine 2.9517 0.3707 2.2217 3.6809 19.1381
PCP 1.3126 0.3548 0.6150 2.0048 3.7158
Methamphetamine 1.1352 0.3489 0.4528 1.8229 3.1118
OxyContin 1.1166 0.4224 0.3055 1.9593 3.0543
Morphine 0.8977 0.5028 -0.1112 1.8628 2.4539
Ecstasy 0.7971 0.3248 0.1603 1.4343 2.2191
Other Stimulants 0.3301 0.4183 -0.5112 1.1344 1.3911
Mescaline 0.2928 0.4665 -0.6312 1.1979 1.3401
Oxycodone (not OxyContin) 0.2716 0.4662 -0.6610 1.1681 1.3121
Psilocybin 0.2359 0.3480 -0.4526 0.9176 1.2660
Other Pain Killers 0.2256 0.4171 -0.6097 1.0290 1.2531
Crack 0.1750 0.3622 -0.5429 0.8757 1.1912
Other Hallucinogens 0.1084 0.9102 -1.8566 1.7172 1.1145
LSD 0.0649 0.3666 -0.6606 0.7794 1.0671
Methadone 0.0205 0.4225 -0.8240 0.8317 1.0207
Tranquilizers -0.2946 0.7654 -1.8808 1.1179 0.7448
Benzos -0.3027 0.7717 -1.7337 1.2857 0.7388
Codeine -0.3049 0.3687 -1.0286 0.4126 0.7372
Dilaudid -0.4328 0.8450 -2.1814 1.1406 0.6487
Youth Years 2003-2005:  70% Sample (Informed Prior)
Beattie | 48  
 
Youth Usage Pattern Analysis (Model Phase Two) 
The parameter values, HDIs, and odds ratios for the youth usage pattern model are shown 
in Appendix G.  As with the adult analysis we restricted our Phase Two analysis to youths who 
had used any of the critical drugs identified in Phase One.  We then modelled the probability of 
heroin use based upon polyabuse of critical drugs, needle use, minimum age of first use of any 
critical drug, prior substance abuse treatment, perceived risk of heroin use, access to heroin, and 
maximum frequency of use of any critical drug.  Fig. 31 shows the results of this analysis for the 
time period 2003-2005, and Fig. 32 shows the relative ranks of the factors across all time 
periods. 
 
Figure 30: Youth Drug Use Ranks and Odds Ratios 
Drug Rank OR Rank OR Rank OR Rank OR
Cocaine 1 19.1381 1 14.8626 1 5.2059 1 11.4210
PCP 2 3.7158 8 2.1782 10 1.8406 12 1.2916
Methamphetamine 3 3.1118 11 1.6281 6 2.5710 10 1.3963
OxyContin 4 3.0543 13 1.3688 17 0.7471 5 2.8702
Morphine 5 2.4539 9 2.0831 2 4.5150 8 1.7896
Ecstasy 6 2.2191 3 2.6789 4 3.1607 4 3.1125
Other Stimulants 7 1.3911 16 0.8555 15 0.9731 14 1.0491
Mescaline 8 1.3401 7 2.2746 13 1.2050 6 2.8601
Oxycodone (not OxyContin) 9 1.3121 12 1.3721 18 0.6410 3 3.3133
Psilocybin 10 1.2660 15 0.9894 7 2.3011 15 0.9525
Other Pain Killers 11 1.2531 5 2.3475 5 2.7638 16 0.8602
Crack 12 1.1912 2 3.3380 9 1.9897 2 3.7705
Other Hallucinogens 13 1.1145 6 2.3057 11 1.7198 7 2.1039
LSD 14 1.0671 4 2.6735 12 1.6167 13 1.2229
Methadone 15 1.0207 17 0.6438 8 2.1128 18 0.8051
Tranquilizers 16 0.7448 18 0.6301 3 3.7040 9 1.5651
Benzos 17 0.7388 10 1.9758 19 0.4688 17 0.8215
Codeine 18 0.7372 14 1.0087 16 0.8160 11 1.3521
Dilaudid 19 0.6487 19 0.4518 14 1.0259 19 0.6183
Youth Ranking and Odds Ratios of Drug Use Flags (Nulls in Red Italic )
2003-2005 2006-2008 2009-2011 2012-2014
Figure 31: Youth Usage Pattern Factors (nulls in red italic) 
Drug Mean SD 2.50% 97.50% OR
Intercept -4.3374 1.0489 -6.4709 -2.3591 1.0000
Access to Heroin 1.0172 0.2775 0.4780 1.5611 2.7655
Needle Use 0.9897 0.4158 0.1661 1.7947 2.6904
Polyabuse 0.9063 0.1235 0.6657 1.1504 2.4753
Perceived Risk 0.6158 0.1622 0.2977 0.9376 1.8511
Prior Treatment 0.0910 0.3049 -0.5165 0.6763 1.0953
Frequency of Use 0.0018 0.0017 -0.0016 0.0051 1.0018
Age of First Use -0.1046 0.0678 -0.2339 0.0310 0.9007
Youth Years 2003-2005:  70% Sample (Informed Prior)
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Figure 32: Youth Usage Pattern Ranks and Odds Ratios 
 For youths, Access to Heroin and Needle Use are the two most important variables across 
all time periods.  Frequency of Use and Age of First Use are the two least important variables, 
and both are null for three of the four time periods.  For this reason, we decided to revise the 
Phase Two youth model by removing these two variables from consideration.  This left us with 
the same model that we saw for the Adult Revised Phase Two Model (Eq. 4).  The youth revised 
model results are shown in Appendix H.  Fig. 33 shows a sample table from 2003-2005, and Fig. 
34 shows the revised ranks and odds ratios across all time periods. 
 
Figure 34:  Revised Youth Usage Pattern Ranks and Odds Ratios 
 Interestingly, we see a significant shift in the ranks of the odds ratios of the youth usage 
pattern factors.  We see Needle Use drop steadily from period to period in importance and we see 
polyabuse grow in importance.  Again, the small datasets could explain some of this variability, 
but the fact that the changes in these two variables occur consistently across all periods lead us to 
believe that there is indeed a consistent usage pattern change for the youth respondents.  We also 
see that the top two factors don’t dominate the results for 2012-2014, where they did in 2003-
2005.  The number of youth heroin users in the 2012-2014 dataset was 101, which is much less 
than 186, the number in the 2003-2005 dataset.  It is possible that as the number of heroin users 
increases in the youth dataset, the usage pattern factor ranks approach those of the adult datasets, 
where needle use is a dominant variable. 
Drug Rank OR Rank OR Rank OR Rank OR
Access to Heroin 1 2.7655 2 3.5766 2 4.7070 2 3.9701
Needle Use 2 2.6904 1 12.2177 1 5.4456 1 7.2955
Polyabuse 3 2.4753 3 2.3531 3 1.8898 3 2.1975
Perceived Risk 4 1.8511 5 1.5766 4 1.5604 5 1.8242
Prior Treatment 5 1.0953 4 1.7719 5 1.4004 4 2.0739
Frequency of Use 6 1.0018 7 1.0003 6 1.0007 7 1.0071
Age of First Use 7 0.9007 6 1.0350 7 0.9369 6 1.0606
Youth Ranking and Odds Ratios of Usage Pattern Flags (Nulls in Red Italic )
2003-2005 2006-2008 2009-2011 2012-2014
Drug Rank OR Rank OR Rank OR Rank OR
Needle Use 1 39.4577 1 13.1143 2 4.5272 4 2.8826
Prior Treatment 2 10.3827 3 3.7468 4 2.0740 3 3.3505
Access to Heroin 3 6.3467 2 4.1153 1 5.2925 2 4.4611
Perceived Risk 4 1.5935 5 1.7179 5 1.4592 5 1.9521
Polyabuse 5 1.0750 4 3.6136 3 2.4963 1 4.9744
Revised Youth Ranking and Odds Ratios of Usage Pattern Flags (Nulls in Red Italic )
2003-2005 2006-2008 2009-2011 2012-2014
Figure 33: Revised Youth Usage Pattern Factors 
Drug Mean SD 2.50% 97.50% OR
Intercept -6.7899 0.1755 -7.1408 -6.4543 1.0000
Needle Use 3.6752 0.3042 3.0694 4.2628 39.4577
Prior Treatment 2.3401 0.2181 1.9036 2.7585 10.3827
Access to Heroin 1.8479 0.1783 1.4984 2.1978 6.3467
Perceived Risk 0.4660 0.1060 0.2577 0.6733 1.5935
Polyabuse 0.0723 0.0234 0.0279 0.1193 1.0750
Revised Youth Years 2003-2005:  70% Sample (Informed Prior)
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Model Validation 
 We focused our validation efforts on the latest dataset, 2012-2014.  We elected to use this 
dataset because our goal is to predict future heroin use, and future use is more likely to follow 
the patterns we see in our most recent dataset.  For both the adult and youth datasets, we applied 
our models to observations that had not been used in model construction.  We began by creating 
diagnostic plots (Figs. 35 and 36).  In these charts, we plot the value for the heroin use flag (1 = 
use, 0 = no use) versus the probability of use calculated by our final revised usage pattern 
models.  We forced a slight jittering of the data points so that we could better see the volume of 
points at any position on the plot. 
 
In the adult plot, we see that the density of the plots of non-users decreases with an increase in 
the probability of use.  The density of the users remains consistent across the probability of use, 
despite the reduction in respondent counts at higher probability levels.  We see a similar pattern 
in the plot for the youth respondents.  These plots show that our models are successfully 
predicting heroin use, but the plots don’t quantify the degree to which the models are accurate.  
Figure 35: Adult Use vs. Probability Figure 36: Youth Use vs. Probability 
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 We validated our models using area under the receiver operating curve (AUROC) as a 
diagnostic metric.  For both the adult and youth revised models, we plotted the ROC (Figs. 37 
and 38).  The AUROC for the adult revised model was 0.9703, which indicates a very good 
model.  The AUROC for the revised youth model was 0.9233 – less than that of the adult model, 
but still a very good score.  From the AUROC scores we can conclude that our revised Phase 
Two models fit both the adult and youth datasets well. 
 Finally, we plotted the distribution of 𝜇 for both the Adult and Youth Revised Models 
(Figs. 39-42).  There are two plots for each model.  The first shows the distribution of 𝜇 for non-
users.  For both the adult and youth datasets, we see that the mean and median values for 𝜇 are 
very low.  The second plot portrays the distribution of 𝜇 for users.  For both datasets, the mean 
and median values for 𝜇 are well above those for the non-users, which we would expect.  
However, those values are lower than 0.5, which means that if we are to use these models for 
classification or prediction of heroin users, the threshold value, the value over which we would 
identify a potential heroin user, is only 0.35 for adults and 0.11 for youths. 
Figure 37: ROC for Revised Adult Model Figure 38: ROC for Revised Youth Model 




 We can draw conclusions from our analysis regarding the methodology of our model.  
These conclusions are relevant to researchers wishing to explore large, complex datasets.  We 
can also draw conclusions about correlates to heroin use.  These conclusions are relevant to 
clinicians and practitioners wishing to impact the opioid crisis.  Before presenting these summary 
findings, we will review some limitations of our study. 
Limitations 
 The most important limitation to our study is that it is based upon data that was 
voluntarily provided by users through surveys.  This means that our findings rely on the accuracy 
and honesty of those surveys.  One way to validate our conclusions would be to use different 
data, such as insurance records, and redo the model using our findings as a set of prior 
distributions.  Another limitation is due to our imputation approach.  In the initial reduction of 
the dataset, we manually imputed data for missing values based upon reasonable assumptions.  
While most of the variables for which we did this were ultimately not important, we could use 
Figure 39: Adult Non-User Distribution of 𝜇 Figure 40: Adult User Distribution of 𝜇 
Figure 41: Youth Non-User Distribution of 𝜇 Figure 42: Youth User Distribution of 𝜇 
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more robust imputation techniques to remove this limitation entirely.  Finally, our method for 
setting prior distributions for model parameters is open to debate.  We chose to set subjective 
priors based upon a review of prior literature.  A competing approach would be to set more 
specific priors using the values for parameters found in that literature.  Given that the studies in 
the literature involved many fewer observations than our dataset, we believe that such an 
approach was unwarranted. 
Methodological Findings 
Traditional medical and epidemiological research begins with a set hypothesis and then 
uses a dataset, sometimes from a clinical study, sometimes from an existing dataset, and 
conducts null hypothesis tests to determine an outcome.  When we are presented with a massive 
dataset from which many hypotheses can be tested, we believe that the data itself should guide 
researchers to important investigations.   
 The NSDUH dataset presents a good example of this situation – it has many 
observations, covers multiple time periods, and has thousands of variables.  When we confront 
such a dataset, we should be able to ask vague questions, such as “what factors are closely 
correlated with heroin use” and let the data guide us to the answers.  Unsupervised methods such 
as principal component analysis and supervised methods such as random forest classification 
trees can uncover variables that should be used by the researcher in model construction.  We 
applied these techniques without restricting the potential variables in the NSDUH dataset that 
could be relevant to our question.  When we did so, we uncovered some variables that we would 
have expected from other studies, such as OxyContin abuse and needle use, and others that had 
not been well studied, such as respondents’ perceived risk of heroin and their ability to acquire 
heroin easily.  Our methods rejected other variables which we may have thought were relevant 
such as sex, race, and other socio-demographic factors. 
 Our methods also incorporated Bayesian statistics, which allowed us to consider previous 
studies when we constructed our models.  When doing research, we should not ignore previous 
studies, especially those based upon other data sources.  Instead, research should either reinforce 
conclusions found elsewhere or refute them by finding them invalid according to a higher 
standard than we would have in the absence of prior knowledge.  Bayesian statistics, through the 
incorporation of prior distributions, accomplishes this goal and in doing so lets a single study 
represent the accumulated knowledge of many.  We drew some conclusions that reinforced prior 
knowledge, such as the correlation between needle use and heroin use.  We also refuted others.  
Despite prior knowledge that suggested a correlation between age of first use and heroin use, our 
study found this relationship to be rejected at the 95% high density interval. 
We advocate the use of our methodology, the application of PCA and classification trees 
to large datasets to determine variables for inclusion in a Bayesian model, on other sources.  We 
are seeing an increase in availability of large medical datasets from Federal, state, and local 
government sources, as well as from insurance providers.  We have reached a point where the 
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volume of data available to researchers requires advanced data analytics in order to uncover new 
and potentially surprising findings that would otherwise be undiscovered by traditional medical 
research techniques 
Heroin Use Findings 
 We were able to quantify correlates to heroin use and how those have changed over time.  
We demonstrated that the impact of OxyContin use has increased since 2003.  The correlation 
between OxyContin and heroin has been well documented, but we have shown that it arose after 
2005 and grew through 2014.  We also showed that while a great deal of attention has been paid 
to the relationship between non-prescription opioids and heroin, cocaine and crack have 
consistently been the drugs most associated with heroin use among adults from 2003 through 
2014.  We found that for both adults and youths, hallucinogen use, especially of PCP and 
ecstasy, was highly correlated to heroin use. 
 We showed that not all drugs are relevant.  Instead, there is a list of critical drugs, which 
differs for adults and youths, that is definitively correlated to heroin use.  For example, we can 
say that there is no evidence in the NSDUH dataset that marijuana use is correlated to heroin use 
for either adults or youths.  This is a significant finding considering the national debate on 
marijuana legalization.  Additionally, we found that not only is the use of critical drugs relevant, 
but other factors related to their use is also important.  The likelihood of heroin use increases 
with the number of critical drugs that a potential user has abused. 
 We found two other factors of interest to practitioners wishing to suppress heroin usage.  
The first of these pertains to access to heroin.  We found that respondents who had easy access to 
heroin were more likely to use it.  While this seems obvious, we had not found any studies that 
considered this relationship.  Advocates of policies regarding decriminalization of heroin use or 
the creation of “safe space” areas for use should take note that they may create unintended 
consequences of increased usage among the population by easing access to the drug.  Similarly, 
respondents with a low perceived risk of heroin use are more likely to use it.  Again, this may 
seem obvious, but by proving the relationship, we are providing evidence that education 
programs for likely users may reduce the chance of heroin use. 
 Our study has created opportunities for further research.  Our parameter values can be 
used to create a likely-heroin-use scoring model.  This model could be used by health care 
providers or counsellors to determine whether more aggressive intervention strategies are 
warranted for potential users.  We recommend a longitudinal clinical study to see if a scoring 
model based upon our findings could reduce heroin use in a population. 
 . 
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rdifher Access Heroin fairly or very easy to obtain Y Y
ircocage Age of First Use Cocaine age of first use Y Y
ircrkage Age of First Use Crack age of first use Y Y
irecsage Age of First Use Ecstasy age of first use Y Y
irhalage Age of First Use Hallucinogens - age of first use Y Y
irlsdage Age of First Use LSD age of first use Y Y
irmthage Age of First Use Methamphetamine - age of first use Y
iroxyage Age of First Use Oxycontin age of first use Y
irpcpage Age of First Use PCP age of first use Y Y
irstmage Age of First Use Stimulants age of first use Y
irtrnage Age of First Use Tranquilizer age of first use Y Y
benzos Ever Used Benzodiazepine products - ever used Y Y
cocflag Ever Used Cocaine - ever used Y Y
CODEINE2 Ever Used Codeine - ever used Y
cpnmthfg Ever Used Methamphetamine - ever used Y
cpnstmfg Ever Used Stimulants - ever used Y
crkflag Ever Used Crack - ever used Y Y
DILAUD2 Ever Used Dilaudid - ever used Y
ecsflag Ever Used Ecstasy - ever used Y
halflag Ever Used Hallucinogens - ever used Y Y
lsdflag Ever Used LSD - ever used Y Y
MESC2 Ever Used Mescaline - ever used Y
METHDON2 Ever Used Methadone - ever used Y Y
MORPHIN2 Ever Used Morphine - ever used Y Y
othanl Ever Used Other pain relievers - ever used Y
OXYCODP2 Ever Used Oxycodone products (excl Oxycontin) - ever used Y Y
oxyflag Ever Used Oxycontin - ever used Y Y
pcpflag Ever Used PCP - ever used Y Y
PSILCY2 Ever Used Psilocybin - ever used Y Y
trqflag Ever Used Tranquilizers - ever used Y Y
ircocfy Frequency Cocaine frequency past year Y
irhalfy Frequency Hallucinogen frequency past year Y
irmthfy Frequency Methamphetamine frequency past year Y
cocneedl Needle Use Ever used needle to inject cocaine Y
mthneedl Needle Use Methamphetamine - ever used needle to inject Y
otdgnedl Needle Use Ever used needle to inject any other drug Y
grskhreg Perceived Risk Great risk - use heroin 1-2 times per week Y
grskhtry Perceived Risk Great risk - trying heroin once or twice Y
txilalev Treatment Received treatment for drug or alcohol use in lifetime Y
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rdifher Access Heroin fairly or very easy to obtain Yes
ircocage Age of First Use Cocaine age of first use Yes
ircrkage Age of First Use Crack age of first use Yes
irecsage Age of First Use Ecstasy age of first use Yes
irhalage Age of First Use Hallucinogens - age of first use Yes
irlsdage Age of First Use LSD age of first use Yes
irmthage Age of First Use Methamphetamine - age of first use Yes
iroxyage Age of First Use Oxycontin age of first use Yes
irpcpage Age of First Use PCP age of first use Yes
irstmage Age of First Use Stimulants age of first use Yes
irtrnage Age of First Use Tranquilizer age of first use Yes
benzos Ever Used Benzodiazepine products - ever used Inconclusive
cocflag Ever Used Cocaine - ever used Yes
CODEINE2 Ever Used Codeine - ever used No
cpnmthfg Ever Used Methamphetamine - ever used Inconclusive
cpnstmfg Ever Used Stimulants - ever used No
crkflag Ever Used Crack - ever used Yes
DILAUD2 Ever Used Dilaudid - ever used Yes
ecsflag Ever Used Ecstasy - ever used No
halflag Ever Used Hallucinogens - ever used No
lsdflag Ever Used LSD - ever used No
MESC2 Ever Used Mescaline - ever used No
METHDON2 Ever Used Methadone - ever used Inconclusive
MORPHIN2 Ever Used Morphine - ever used No
othanl Ever Used Other pain relievers - ever used No
onlyoxycod Ever Used Oxycodone products (excl Oxycontin) - ever used Inconclusive
oxyflag Ever Used Oxycontin - ever used Strong
pcpflag Ever Used PCP - ever used No
PSILCY2 Ever Used Psilocybin - ever used No
trqflag Ever Used Tranquilizers - ever used Inconclusive
ircocfy Frequency Cocaine frequency past year No
irhalfy Frequency Hallucinogen frequency past year No
irmthfy Frequency Methamphetamine frequency past year No
cocneedl Needle Use Ever used needle to inject cocaine Strong
mthneedl Needle Use Methamphetamine - ever used needle to inject No
otdgnedl Needle Use Ever used needle to inject any other drug Strong
grskhreg Perceived Risk Great risk - use heroin 1-2 times per week No
grskhtry Perceived Risk Great risk - trying heroin once or twice No
txilalev Treatment Received treatment for drug or alcohol use in lifetime No
polyabuse Ever Used Constructed flag for multiple high risk drug use Yes
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Appendix C:  Adult Phase One Gibbs Sampling Results (Null in Red Italic) 
 
  
Drug Mean SD 2.50% 97.50% OR
Intercept -7.0472 0.1744 -7.4053 -6.7184 1.0000
Cocaine 2.7466 0.2048 2.3550 3.1583 15.5895
Crack 1.5521 0.1004 1.3564 1.7495 4.7213
Dilaudid 0.8575 0.2124 0.4398 1.2725 2.3573
Methadone 0.8470 0.1639 0.5251 1.1670 2.3326
PCP 0.7317 0.1109 0.5148 0.9493 2.0785
Tranquilizers 0.7285 0.2966 0.1408 1.3035 2.0721
Mescaline 0.6997 0.1126 0.4775 0.9201 2.0131
LSD 0.6831 0.1313 0.4246 0.9377 1.9800
Morphine 0.6023 0.2064 0.1959 1.0045 1.8262
Oxycodone (not OxyContin) 0.3053 0.1375 -0.0360 0.5756 1.3571
Ecstasy 0.2997 0.1073 0.0891 0.5090 1.3495
OxyContin 0.2856 0.1640 -0.0349 0.6058 1.3306
Other Pain Killers 0.2570 0.1468 -0.0349 0.5425 1.2931
Codeine 0.0120 0.1356 -0.2543 0.2784 1.0121
Psilocybin -0.0413 0.1189 -0.2738 0.1917 0.9595
Other Stimulants -0.0705 0.1540 -0.3755 0.2264 0.9319
Other Hallucinogens -0.1996 0.6916 -1.6655 1.0316 0.8190
Benzos -0.2659 0.2930 -0.8311 0.3170 0.7665
Methamphetamine -0.3371 0.1153 -0.5638 -0.1120 0.7139
Adult Years 2003-2005:  50% Sample (Informed Prior)
Drug Mean SD 2.50% 97.50% OR
Intercept -6.7543 0.1288 -7.0146 -6.5113 1.0000
Cocaine 2.4734 0.1560 2.1761 2.7862 11.8626
Crack 1.4614 0.0829 1.2997 1.6246 4.3120
PCP 0.9691 0.0936 0.7853 1.1521 2.6355
Dilaudid 0.8959 0.1572 0.5880 1.2042 2.4495
LSD 0.6243 0.1003 0.4274 0.8191 1.8669
Morphine 0.6179 0.1680 0.2833 0.9433 1.8551
OxyContin 0.5495 0.1391 0.2813 0.8240 1.7323
Methadone 0.4918 0.1306 0.2354 0.7461 1.6352
Mescaline 0.4429 0.1002 0.2465 0.6397 1.5572
Other Hallucinogens 0.4171 0.4788 -0.5993 1.2805 1.5175
Ecstasy 0.3469 0.0897 0.1705 0.5210 1.4146
Oxycodone (not OxyContin) 0.2914 0.1209 0.0542 0.5283 1.3383
Benzos 0.2901 0.3101 -0.2850 0.9428 1.3366
Other Pain Killers 0.0927 0.1270 -0.1587 0.3382 1.0971
Methamphetamine 0.0360 0.0930 -0.1467 0.2178 1.0367
Psilocybin 0.0243 0.0961 -0.1640 0.2119 1.0246
Other Stimulants -0.0051 0.1304 -0.2628 0.2486 0.9949
Tranquilizers -0.0350 0.3138 -0.6894 0.5485 0.9656
Codeine -0.0462 0.1111 -0.2637 0.1715 0.9549
Adult Years 2006-2008:  50% Sample (Informed Prior)
Drug Mean SD 2.50% 97.50% OR
Intercept -6.7367 0.1229 -6.9820 -6.5021 1.0000
Cocaine 2.6650 0.1468 2.3820 2.9538 14.3677
Crack 1.4697 0.0791 1.3152 1.6246 4.3479
PCP 0.7874 0.0968 0.5981 0.9769 2.1977
Methadone 0.7346 0.1162 0.5066 0.9635 2.0846
Dilaudid 0.6642 0.1440 0.0382 0.9471 1.9429
OxyContin 0.6172 0.1311 0.3636 0.8770 1.8538
Mescaline 0.5987 0.0977 0.4057 0.7901 1.8197
Ecstasy 0.5475 0.0835 0.3852 0.7126 1.7288
Morphine 0.5382 0.1637 0.2123 0.8542 1.7128
LSD 0.3930 0.0898 0.2171 0.5699 1.4814
Tranquilizers 0.2916 0.2939 -0.3098 0.8536 1.3386
Other Stimulants 0.2288 0.1094 0.0135 0.4419 1.2570
Methamphetamine 0.0997 0.0893 -0.0764 0.2741 1.1048
Oxycodone (not OxyContin) 0.0831 0.1191 -0.1497 0.3185 1.0866
Other Pain Killers 0.0788 0.1235 -0.1686 0.3182 1.0820
Other Hallucinogens 0.0663 0.4701 -0.9195 0.9182 1.0686
Codeine 0.0419 0.1018 -0.2406 0.1572 1.0427
Benzos 0.0129 0.2905 -0.5374 0.6075 1.0130
Psilocybin -0.0659 0.0912 -0.2454 0.1121 0.9363
Adult Years 2009-2011:  50% Sample (Informed Prior)
Drug Mean SD 2.50% 97.50% OR
Intercept -6.4759 0.1054 -6.6857 -6.2740 1.0000
Cocaine 2.4325 0.1304 2.1803 2.6902 11.3874
Crack 1.3085 0.0802 1.1526 1.4660 3.7005
OxyContin 0.9810 0.1357 0.7167 1.2488 2.6672
PCP 0.9388 0.0970 0.7489 1.1287 2.5568
Dilaudid 0.7803 0.1276 0.5294 1.0302 2.1821
Morphine 0.7703 0.1607 0.4539 1.0825 2.1604
Methadone 0.5475 0.1158 0.3200 0.7754 1.7290
Oxycodone (not OxyContin) 0.5392 0.1182 0.3056 0.7702 1.7146
Benzos 0.5227 0.3666 -0.0171 1.2723 1.6866
Ecstasy 0.4592 0.0848 0.2923 0.0626 1.5827
Mescaline 0.4263 0.1029 0.2237 0.6264 1.5315
LSD 0.3594 0.0901 0.1834 0.5371 1.4325
Methamphetamine 0.2640 0.0886 0.0910 0.4376 1.3021
Other Pain Killers 0.0790 0.1247 -0.1665 0.3200 1.0822
Tranquilizers -0.0877 0.3692 -0.8422 0.6148 0.9161
Psilocybin -0.1097 0.0911 -0.2890 0.0677 0.8961
Other Stimulants -0.1451 0.1159 -0.3754 0.0801 0.8649
Codeine -0.2529 0.1029 -0.4543 -0.0516 0.7766
Other Hallucinogens -0.8445 0.6550 -2.2389 0.3249 0.4298
Adult Years 2012-2014:  50% Sample (Informed Prior)
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Drug Mean SD 2.50% 97.50% OR
Intercept -5.5831 0.2498 -6.0731 -5.0935 1.0000
Needle Use 1.4793 0.1031 1.2776 1.6819 4.3898
Access to Heroin 1.3083 0.0816 1.1487 1.4676 3.7000
Prior Treatment 0.6782 0.0827 0.5167 0.8399 1.9703
Perceived Risk 0.6122 0.0576 0.4990 0.7252 1.8444
Polyabuse 0.5105 0.0207 0.4701 0.5514 1.6661
Age of First Use -0.0037 0.0113 -0.0261 0.0180 0.9963
Adult Years 2003-2005:  50% Sample (Informed Prior)
Drug Mean SD 2.50% 97.50% OR
Intercept -5.6274 0.2524 -6.1223 -5.1329 1.0000
Needle Use 1.7855 0.1071 1.5745 1.9933 5.9625
Access to Heroin 1.0854 0.0868 0.9148 1.2554 2.9607
Prior Treatment 0.7011 0.0870 0.5295 0.8695 2.0161
Perceived Risk 0.6609 0.0606 0.5421 0.7796 1.9365
Polyabuse 0.5841 0.0231 0.5393 0.6298 1.7934
Age of First Use 0.0001 0.0114 -0.0228 0.0223 1.0001
Adult Years 2006-2008:  50% Sample (Informed Prior)
Drug Mean SD 2.50% 97.50% OR
Intercept -4.8827 0.2489 -5.3717 -4.3987 1.0000
Needle Use 1.7589 0.1049 1.5539 1.9646 5.8058
Access to Heroin 1.0604 0.0814 0.9013 1.2196 2.8875
Perceived Risk 0.6379 0.0555 0.5286 0.7462 1.8925
Prior Treatment 0.5865 0.0812 0.4268 0.7455 1.7977
Polyabuse 0.5712 0.0213 0.5298 0.6130 1.7704
Age of First Use -0.0275 0.0120 -0.0512 -0.0043 0.9728
Adult Years 2009-2011:  50% Sample (Informed Prior)
Drug Mean SD 2.50% 97.50% OR
Intercept -4.8569 0.2332 -5.3136 -4.3963 1.0000
Needle Use 1.5758 0.1023 1.3764 1.7761 4.8345
Access to Heroin 1.2202 0.0786 1.0668 1.3746 3.3878
Prior Treatment 0.8257 0.0798 0.6691 0.9808 2.2835
Perceived Risk 0.6776 0.0556 0.5690 0.7866 1.9691
Polyabuse 0.4807 0.0178 0.4463 0.5158 1.6172
Age of First Use -0.0306 0.0109 -0.0522 -0.0095 0.9699
Adult Years 2012-2014:  50% Sample (Informed Prior)
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Appendix E:  Revised Adult Phase Two Gibbs Sampling Results 
  
Drug Mean SD 2.50% 97.50% OR
Intercept -6.6272 0.9081 -6.8090 -6.4524 1.0000
Needle Use 1.5487 0.1104 1.3301 1.7633 4.7053
Access to Heroin 1.2778 0.0815 1.1181 1.4374 3.5887
Prior Treatment 0.8380 0.0869 0.6670 1.0077 2.3117
Polyabuse 0.6830 0.0166 0.6508 0.7160 1.9798
Perceived Risk 0.6261 0.0586 0.5104 0.7405 1.8703
 Revised Adult Years 2003-2005:  50% Sample (Informed Prior)
Drug Mean SD 2.50% 97.50% OR
Intercept -6.5278 0.0894 -6.7059 -6.3542 1.0000
Needle Use 1.8820 0.1103 1.6652 2.0964 6.5666
Access to Heroin 1.0956 0.0861 0.9253 1.2634 2.9910
Prior Treatment 0.7943 0.0913 0.6151 0.9720 2.2129
Polyabuse 0.7554 0.0185 0.7193 0.7917 2.1285
Perceived Risk 0.5832 0.0600 0.4655 0.7001 1.7918
Revised Adult Years 2006-2008:  50% Sample (Informed Prior)
Drug Mean SD 2.50% 97.50% OR
Intercept -6.3796 0.0834 -6.5452 -6.2177 1.0000
Needle Use 1.7114 0.1123 1.4924 1.9311 5.5367
Access to Heroin 1.1184 0.0805 0.9599 1.2768 3.0600
Polyabuse 0.7688 0.0174 0.7350 0.8032 2.1572
Prior Treatment 0.7616 0.0848 0.5957 0.9273 2.1417
Perceived Risk 0.5609 0.0553 0.4529 0.6686 1.7522
Revised Adult Years 2009-2011:  50% Sample (Informed Prior)
Drug Mean SD 2.50% 97.50% OR
Intercept -6.4847 0.0852 -6.6551 -6.3200 1.0000
Needle Use 1.7237 0.1097 1.5089 1.9377 5.6052
Access to Heroin 1.3691 0.0791 1.2140 1.5242 3.9318
Prior Treatment 0.9924 0.0856 0.8230 1.1580 2.6977
Perceived Risk 0.7205 0.0540 0.6145 0.8265 2.0555
Polyabuse 0.6259 0.0151 0.5967 0.6558 1.8699
Revised Adult Years 2012-2014:  50% Sample (Informed Prior)
Beattie | 60  
 
Appendix F:  Youth Phase One Gibbs Sampling Results (Null in Red Italic) 
  
Drug Mean SD 2.50% 97.50% OR
Intercept -7.1958 0.2175 -7.6401 -6.7917 1.0000
Cocaine 2.9517 0.3707 2.2217 3.6809 19.1381
PCP 1.3126 0.3548 0.6150 2.0048 3.7158
Methamphetamine 1.1352 0.3489 0.4528 1.8229 3.1118
OxyContin 1.1166 0.4224 0.3055 1.9593 3.0543
Morphine 0.8977 0.5028 -0.1112 1.8628 2.4539
Ecstasy 0.7971 0.3248 0.1603 1.4343 2.2191
Other Stimulants 0.3301 0.4183 -0.5112 1.1344 1.3911
Mescaline 0.2928 0.4665 -0.6312 1.1979 1.3401
Oxycodone (not OxyContin) 0.2716 0.4662 -0.6610 1.1681 1.3121
Psilocybin 0.2359 0.3480 -0.4526 0.9176 1.2660
Other Pain Killers 0.2256 0.4171 -0.6097 1.0290 1.2531
Crack 0.1750 0.3622 -0.5429 0.8757 1.1912
Other Hallucinogens 0.1084 0.9102 -1.8566 1.7172 1.1145
LSD 0.0649 0.3666 -0.6606 0.7794 1.0671
Methadone 0.0205 0.4225 -0.8240 0.8317 1.0207
Tranquilizers -0.2946 0.7654 -1.8808 1.1179 0.7448
Benzos -0.3027 0.7717 -1.7337 1.2857 0.7388
Codeine -0.3049 0.3687 -1.0286 0.4126 0.7372
Dilaudid -0.4328 0.8450 -2.1814 1.1406 0.6487
Youth Years 2003-2005:  70% Sample (Informed Prior)
Drug Mean SD 2.50% 97.50% OR
Intercept -7.6004 0.2181 -8.0453 -7.1922 1.0000
Cocaine 2.6988 0.3660 1.9800 3.4134 14.8626
Crack 1.2054 0.3131 0.5930 1.8250 3.3380
Ecstasy 0.9854 0.3249 0.3552 1.6228 2.6789
LSD 0.9834 0.3284 0.3387 1.6269 2.6735
Other Pain Killers 0.8533 0.3733 0.1098 1.5728 2.3475
Other Hallucinogens 0.8354 0.6567 -0.5439 2.0223 2.3057
Mescaline 0.8218 0.4174 -0.0005 1.6364 2.2746
PCP 0.7785 0.3481 0.0920 1.4578 2.1782
Morphine 0.7339 0.4866 -0.2344 1.6796 2.0831
Benzos 0.6810 0.7154 -0.6366 2.1694 1.9758
Methamphetamine 0.4874 0.3286 -0.1632 1.1272 1.6281
Oxycodone (not OxyContin) 0.3163 0.4353 -0.5636 1.1484 1.3721
OxyContin 0.3139 0.3859 -0.4338 1.0743 1.3688
Codeine 0.0087 0.3303 -0.6413 0.6528 1.0087
Psilocybin -0.0107 0.3414 -0.6820 0.6625 0.9894
Other Stimulants -0.1561 0.3822 -0.9301 0.5701 0.8555
Methadone -0.4403 0.3874 -1.2118 0.3080 0.6438
Tranquilizers -0.4619 0.7241 -1.9614 0.8795 0.6301
Dilaudid -0.7945 0.7222 -2.2809 0.5518 0.4518
Youth Years 2006-2008:  70% Sample (Informed Prior)
Drug Mean SD 2.50% 97.50% OR
Intercept -7.0499 0.1653 -7.3837 -6.7361 1.0000
Cocaine 1.6498 0.3196 1.0245 2.2769 5.2059
Morphine 1.5074 0.4387 0.6371 2.3565 4.5150
Tranquilizers 1.3094 0.6232 0.0148 2.4472 3.7040
Ecstasy 1.1508 0.3182 0.5325 1.7747 3.1607
Other Pain Killers 1.0166 0.3448 0.3267 1.6766 2.7638
Methamphetamine 0.9443 0.3280 0.2972 1.5804 2.5710
Psilocybin 0.8334 0.3073 0.2277 1.4384 2.3011
Methadone 0.7480 0.3204 0.1143 1.3714 2.1128
Crack 0.6880 0.3392 0.0201 1.3473 1.9897
PCP 0.6101 0.3370 -0.0575 1.2609 1.8406
Other Hallucinogens 0.5422 0.7491 -1.0590 1.8749 1.7198
LSD 0.4804 0.3066 -0.1237 1.0777 1.6167
Mescaline 0.1865 0.4210 -0.6427 1.0029 1.2050
Dilaudid 0.0256 0.6692 -1.3288 1.3153 1.0259
Other Stimulants -0.0273 0.3623 -0.7549 0.6671 0.9731
Codeine -0.2034 0.3089 -0.8119 0.3984 0.8160
OxyContin -0.2915 0.3667 -1.0055 0.4311 0.7471
Oxycodone (not OxyContin) -0.4447 0.4477 -1.3513 0.4037 0.6410
Benzos -0.7576 0.6227 -1.9017 0.5244 0.4688
Youth Years 2009-2011:  70% Sample (Informed Prior)
Drug Mean SD 2.50% 97.50% OR
Intercept -7.1976 0.1913 -7.5878 -6.8377 1.0000
Cocaine 2.4355 0.4429 1.5718 3.3065 11.4210
Crack 1.3272 0.4587 0.4241 2.2192 3.7705
Oxycodone (not OxyContin) 1.1979 0.5009 0.1778 2.1506 3.3133
Ecstasy 1.1354 0.4583 0.2356 2.0289 3.1125
OxyContin 1.0544 0.5040 0.0679 2.0474 2.8702
Mescaline 1.0508 0.5773 -0.1055 2.1583 2.8601
Other Hallucinogens 0.7438 0.8090 -0.9503 2.2085 2.1039
Morphine 0.5820 0.5561 -0.5284 1.6490 1.7896
Tranquilizers 0.4480 0.8529 -1.2883 2.0428 1.5651
Methamphetamine 0.3338 0.4409 -0.5448 1.1858 1.3963
Codeine 0.3017 0.4413 -0.5528 1.1709 1.3521
PCP 0.2559 0.4577 -0.6550 1.1479 1.2916
LSD 0.2012 0.4549 -0.6789 1.0976 1.2229
Other Stimulants 0.0479 0.4837 -0.9229 0.9775 1.0491
Psilocybin -0.0487 0.4167 -0.8756 0.7620 0.9525
Other Pain Killers -0.1506 0.5012 -1.1641 0.8030 0.8602
Benzos -0.1967 0.8546 -1.8013 1.5441 0.8215
Methadone -0.2168 0.4928 -1.1922 0.7402 0.8051
Dilaudid -0.4807 0.8632 -2.2634 1.1257 0.6183
Youth Years 2012-2014:  70% Sample (Informed Prior)
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Appendix G:  Youth Phase Two Gibbs Sampling Results (Null in Red Italic) 
  
Drug Mean SD 2.50% 97.50% OR
Intercept -4.3374 1.0489 -6.4709 -2.3591 1.0000
Access to Heroin 1.0172 0.2775 0.4780 1.5611 2.7655
Needle Use 0.9897 0.4158 0.1661 1.7947 2.6904
Polyabuse 0.9063 0.1235 0.6657 1.1504 2.4753
Perceived Risk 0.6158 0.1622 0.2977 0.9376 1.8511
Prior Treatment 0.0910 0.3049 -0.5165 0.6763 1.0953
Frequency of Use 0.0018 0.0017 -0.0016 0.0051 1.0018
Age of First Use -0.1046 0.0678 -0.2339 0.0310 0.9007
Youth Years 2003-2005:  70% Sample (Informed Prior)
Drug Mean SD 2.50% 97.50% OR
Intercept -6.8528 0.9338 -8.7801 -5.1098 1.0000
Needle Use 2.5029 0.3544 1.8074 3.1953 12.2177
Access to Heroin 1.2744 0.2605 0.7641 1.7867 3.5766
Polyabuse 0.8557 0.0935 0.6750 1.0413 2.3531
Prior Treatment 0.5721 0.2822 0.0096 1.1128 1.7719
Perceived Risk 0.4552 0.1543 0.1501 0.7554 1.5766
Age of First Use 0.0344 0.0609 -0.0812 0.1577 1.0350
Frequency of Use 0.0003 0.0017 -0.0031 0.0035 1.0003
Youth Years 2006-2008:  70% Sample (Informed Prior)
Drug Mean SD 2.50% 97.50% OR
Intercept -5.5754 0.7243 -7.0464 -4.2107 1.0000
Needle Use 1.6948 0.3764 0.9564 2.4303 5.4456
Access to Heroin 1.5490 0.2415 1.0785 2.0260 4.7070
Polyabuse 0.6365 0.0698 0.5008 0.7752 1.8898
Perceived Risk 0.4450 0.1464 0.1549 0.7295 1.5604
Prior Treatment 0.3368 0.2865 -0.2315 0.8859 1.4004
Frequency of Use 0.0007 0.0014 -0.0022 0.0035 1.0007
Age of First Use -0.0652 0.0474 -0.1547 0.0304 0.9369
Youth Years 2009-2011:  70% Sample (Informed Prior)
Drug Mean SD 2.50% 97.50% OR
Intercept -7.0220 1.5457 -10.1357 -4.1107 1.0000
Needle Use 1.9873 0.4365 1.1301 2.8448 7.2955
Access to Heroin 1.3788 0.3268 0.7430 2.0219 3.9701
Polyabuse 0.7873 0.1711 0.4539 1.1258 2.1975
Prior Treatment 0.7294 0.3376 0.0563 1.3812 2.0739
Perceived Risk 0.6011 0.2017 0.2056 0.9978 1.8242
Age of First Use 0.0588 0.0973 -0.1273 0.2545 1.0606
Frequency of Use 0.0070 0.0022 0.0027 0.0113 1.0071
Youth Years 2012-2014:  70% Sample (Informed Prior)
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Appendix H:  Revised Youth Phase Two Gibbs Sampling Results 









Drug Mean SD 2.50% 97.50% OR
Intercept -6.7899 0.1755 -7.1408 -6.4543 1.0000
Needle Use 3.6752 0.3042 3.0694 4.2628 39.4577
Prior Treatment 2.3401 0.2181 1.9036 2.7585 10.3827
Access to Heroin 1.8479 0.1783 1.4984 2.1978 6.3467
Perceived Risk 0.4660 0.1060 0.2577 0.6733 1.5935
Polyabuse 0.0723 0.0234 0.0279 0.1193 1.0750
Revised Youth Years 2003-2005:  70% Sample (Informed Prior)
Drug Mean SD 2.50% 97.50% OR
Intercept -8.2731 0.2762 -8.8355 -7.7560 1.0000
Needle Use 2.5737 0.3916 1.7932 3.3350 13.1143
Access to Heroin 1.4147 0.2575 0.9095 1.9170 4.1153
Prior Treatment 1.3209 0.2972 0.7297 1.8970 3.7468
Polyabuse 1.2847 0.0777 1.1327 1.4380 3.6136
Perceived Risk 0.5411 0.1582 0.2304 0.8490 1.7179
Revised Youth Years 2006-2008:  70% Sample (Informed Prior)
Drug Mean SD 2.50% 97.50% OR
Intercept -7.7509 0.2219 -8.2006 -7.3292 1.0000
Access to Heroin 1.6663 0.2195 1.2354 2.0962 5.2925
Needle Use 1.5101 0.3975 0.7319 2.2862 4.5272
Polyabuse 0.9148 0.0491 0.8183 1.0111 2.4963
Prior Treatment 0.7295 0.2802 0.1675 1.2713 2.0740
Perceived Risk 0.3779 0.1309 0.1215 0.6359 1.4592
Revised Youth Years 2009-2011:  70% Sample (Informed Prior)
Drug Mean SD 2.50% 97.50% OR
Intercept -8.0889 0.2856 -8.6721 -7.5526 1.0000
Polyabuse 1.6043 0.1180 1.3726 1.8347 4.9744
Access to Heroin 1.4954 0.2838 0.9346 2.0479 4.4611
Prior Treatment 1.2091 0.3581 0.4966 1.9041 3.3505
Needle Use 1.0587 0.5081 0.0489 2.0413 2.8826
Perceived Risk 0.6689 0.1652 0.3455 0.9941 1.9521
Revised Youth Years 2012-2014:  730% Sample (Informed Prior)
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